US20200375982A1 - Treatment of gliomas using organonitro compound combination therapy - Google Patents

Treatment of gliomas using organonitro compound combination therapy Download PDF

Info

Publication number
US20200375982A1
US20200375982A1 US16/712,148 US201916712148A US2020375982A1 US 20200375982 A1 US20200375982 A1 US 20200375982A1 US 201916712148 A US201916712148 A US 201916712148A US 2020375982 A1 US2020375982 A1 US 2020375982A1
Authority
US
United States
Prior art keywords
abdnaz
dose
patient
formulation
temozolomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/712,148
Inventor
Bryan T. Oronsky
Jan Scicinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epicentrx Inc
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Priority to US16/712,148 priority Critical patent/US20200375982A1/en
Publication of US20200375982A1 publication Critical patent/US20200375982A1/en
Priority to US17/223,422 priority patent/US11701351B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Definitions

  • the invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
  • Gliomas are tumors that arise from glial tissue of the brain. Gliomas are often found in the cerebral hemispheres of the brain, but can be found anywhere in the brain. Because gliomas can grow rapidly, common symptoms experienced by patients suffering from a glioma are often associated with an increased pressure in the brain. The symptoms can include headache, nausea, vomiting, and drowsiness. In addition, patients suffering from a glioma may develop other symptoms such as weakness on one side of the body, memory and/or speech difficulties, and visual changes, often as function of the location of the glioma tumor.
  • Gliomas can be characterized according to grade, where low-grade gliomas [WHO grade II] are typically well-differentiated and tend to exhibit benign tendencies. Low-grade gliomas stand in contrast to high-grade gliomas [WHO grade III or IV] that are typically undifferentiated and frequently malignant.
  • WHO grade II low-grade gliomas
  • WHO grade III or IV high-grade gliomas
  • One example of a high-grade glioma is glioblastoma multiforme. Glioblastoma multiforme has been characterized as a World Health Organization grade IV astrocytoma, with an incidence in North America of 5.0 per 100,000 in the population, representing 15 to 20% of all primary intracranial neoplasms.
  • a typical first step in treating a glioblastoma is to surgically remove as much tumor as possible. This can help alleviate pressure on the brain.
  • glioblastomas often have finger-like tentacles, and as a result it can be difficult to completely remove all the glioblastoma. This is particularly true when a glioblastoma appears near parts of the brain that control important functions, such as language and coordination.
  • Radiation and chemotherapy may be used to help slow the growth of glioblastoma tumors that cannot be removed with surgery.
  • survival rates are low using current standard treatments for glioblastoma.
  • the median survival time for adults with an anaplastic astrocytoma has been reported to be about two to three years.
  • the five-year survival rate has been reported to be about twenty-five percent.
  • the invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
  • the compound ABDNAZ has the following chemical structure:
  • the therapeutic methods and kits provide a solution to the long unmet need for a more effective treatment for patients suffering from a glioma.
  • the therapeutic method generally entails (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, irinotecan, or bevacizumab, and within a certain amount of time (e.g., about 7 days) subjecting the glioma to radiation therapy, and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide, irinotecan, or bevacizumab, in order to treat the glioma.
  • the radiation therapy may be administered to the patient for a select number of days (e.g., at least 2, 3, 4, or 5 days) over a two-week period, or longer duration of time depending on patient response to the therapy.
  • the formulation comprising ABDNAZ may be administered to the patient for a select number of days per week (e.g., at least 2, 3, or 4 days per week) over a two-week period, or longer duration of time depending on patient response to the therapy.
  • the therapy may be used to treat various types of gliomas, such as, for example, a primary glioblastoma or a secondary glioblastoma.
  • one aspect of the invention provides a method of treating a glioma in a patient.
  • the method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma.
  • Another aspect of the invention provides a method of treating a glioma in a patient.
  • the method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
  • Another aspect of the invention provides a method of treating a glioma in a patient.
  • the method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising bevacizumab, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the bevacizumab; to treat the glioma.
  • kits for treating a glioma comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma according to procedures described herein, such as (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma.
  • the kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma that comprise (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
  • FIG. 1 is a graph showing response observed using a GBM14 TMZ-S patient-derived cell line, as described in Example 3.
  • FIG. 2 is a graph showing response observed using a GBM14 TMZ-R patient-derived cell line, as described in Example 3.
  • FIG. 3 is a graph showing response observed using cells from temozolomide-resistant murine EGFRvIII/Arfko neural stem cell-derived glioma (NSCG) cell line, as described in Example 4.
  • NSCG neural stem cell-derived glioma
  • FIG. 4 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started five days after intracranial injection of NSCG cells, as described in Example 5.
  • treatment i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide
  • FIG. 5 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started ten days after intracranial injection of NSCG cells, as described in Example 5.
  • treatment i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide
  • FIG. 6 is a graph showing the amount of CC3+ cell apoptosis detected in the assay, as described in Example 6.
  • FIG. 7 is a graph showing the amount of TMZ (mg) detected per gram of tissue analyzed, as described in Example 7.
  • FIG. 8 is a graph showing the amount of irinotecan ( ⁇ g) detected per milligram of tissue analyzed, as described in Example 8.
  • the invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
  • the compound ABDNAZ has the following chemical structure:
  • the therapeutic methods and kits provide a solution to the long unmet need for a more effective treatment for patients suffering from a glioma.
  • the therapeutic method generally entails (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, irinotecan, or bevacizumab, and within a certain amount of time (e.g., about 7 days) subjecting the glioma to radiation therapy, and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide, irinotecan, or bevacizumab, in order to treat the glioma.
  • the radiation therapy may be administered to the patient for a select number of days (e.g., at least 2, 3, 4, or 5 days) over a two-week period, or longer duration of time depending on patient response to the therapy.
  • the formulation comprising ABDNAZ may be administered to the patient for a select number of days per week (e.g., at least 2, 3, or 4 days per week) over a two-week period, or longer duration of time depending on patient response to the therapy.
  • the therapy may be used to treat various types of gliomas, such as, for example, a primary glioblastoma or a secondary glioblastoma.
  • the invention provides therapeutic methods for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
  • the therapeutic methods provide a solution to the long unmet need for a more effective treatment for patients suffering from a glioma.
  • the therapeutic method generally entails (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, irinotecan, or bevacizumab, and within a certain amount of time (e.g., about 7 days) subjecting the glioma to radiation therapy, and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide, irinotecan, or bevacizumab, in order to treat the glioma.
  • the invention also provides methods for increasing the amount of temozolomide, irinotecan, or bevacizumab in a glioma.
  • the method generally involves administering to a patient having a glioma (i) a first formulation comprising temozolomide, irinotecan, or bevacizumab and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the temozolomide, irinotecan, or bevacizumab is present in the patient, in order to increase the amount of the temozolomide, irinotecan, or bevacizumab in the glioma.
  • sections are arranged for convenience and information in one section is not limited to that section, but may be applied to other sections.
  • One aspect of the invention provides a method of treating a glioma in a patient.
  • the method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma.
  • the patient receives temozolomide by oral administration at a daily dose of at least 50 mg/m 2 . In certain embodiments, the patient receives temozolomide by oral administration at a daily dose of about 50 mg/m 2 to about 100 mg/m 2 . In certain embodiments, the patient receives temozolomide by oral administration at a daily dose of about 75 mg/m 2 .
  • a formulation comprising ABDNAZ may be administered multiple times, such as multiple times over a defined period of time. Further, coordination of the dosing schedule of the temozolomide and radiation therapy with that of the formulation comprising ABDNAZ is contemplated to provide therapeutic benefits, such as superior efficacy.
  • the patient receives at least one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of temozolomide, the patient receives at least one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the patient receives at least one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • two doses of a therapeutically effective amount of a formulation comprising ABDNAZ are administered within about 7 days of administration of the first dose of temozolomide.
  • the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • for a duration of at least 6 weeks following administration of the first dose of temozolomide the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of temozolomide, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of 6 weeks following administration of the first dose of temozolomide, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • the patient receives ABDNAZ within about 3 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 6 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 24 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 48 hours prior to subjecting the glioma to radiation therapy.
  • the formulation comprising ABDNAZ is administered so that the ABDNAZ exerts physiological activity during an overlapping time period with one or both of the radiation therapy and temozolomide.
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2 mg/m 2 to about 20 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2.5 mg/m 2 to about 5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m 2 to about 10 mg/m 2 .
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 10 mg/m 2 to about 16.5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 2.5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 10 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 16.5 mg/m 2 .
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 20 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 10 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.5 mg to about 4.0 mg.
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, or 4.0 mg.
  • the method can be further characterized according to the dosing schedule and amount of radiation administered for the radiation therapy.
  • the glioma is subjected to radiation therapy once per day for at least 3 days within a 7 day period following administration of the first dose of temozolomide. In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 5 days within a 7 day period following administration of the first dose of temozolomide. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 3 days of each week.
  • the glioma for a duration of at least 4 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 3 days of each week. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 3 days of each week. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 5 days of each week.
  • the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for 5 days each week. In certain embodiments, for a duration of 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for 5 days each week.
  • the amount of radiation provided to the glioma on the day of administering the radiation therapy is from about 1 Gy to about 3 Gy. In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is about 2 Gy. In certain embodiments, the glioma is exposed to from about 50 Gy to about 70 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of temozolomide. In certain embodiments, the glioma is exposed to about 60 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of temozolomide.
  • the radiation therapy is (i) conventional fractionated external beam radiation or (ii) intensity-modulated radiation therapy. In certain embodiments, the radiation therapy is conventional fractionated external beam radiation.
  • exemplary types of radiation therapy include, for example, radiation therapy comprising gamma rays, X-rays, electron beams, neutron beams, particulate radiation, proton beams, or the like.
  • the source of the radiation is desirably external to the patient, which involves directing a beam of high-energy radiation to the glioma using a machine external to the patient.
  • the target site i.e., site of the glioma
  • the target site is exposed to the radiation therapy for a short duration of time, such as less than about 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute for each dose of radiation therapy.
  • the method may be further characterized according to the scope of the rest period/maintenance period. For example, in certain embodiments, after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks.
  • the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least three days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least two weeks.
  • the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 1 month.
  • the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five consecutive days during the first week of each 28 day period, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 4 months.
  • the patient after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks.
  • the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least three days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least two weeks.
  • the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 1 month.
  • the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five consecutive days during the first week of each 28 day period, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 4 months.
  • the patient after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of about 3 weeks to about 6 weeks.
  • the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of at least 150 mg/m 2 . In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m 2 .
  • the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of from about 75 mg/m 2 to about 400 mg/m 2 . In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of from about 150 mg/m 2 to about 350 mg/m 2 .
  • the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of about 150 mg/m 2 , 200 mg/m 2 , 250 mg/m 2 , 300 mg/m 2 , or 350 mg/m 2 .
  • the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 10 mg. In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.5 mg to about 4.0 mg.
  • the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 0.5 mg, 1.0 mg, 1.5, mg, 2.0 mg, 2.5 mg, 3.0 mg, or 4.0 mg.
  • a therapeutic method for treating a glioblastoma by administering to a patient in need thereof (a) for a duration of at least 3 weeks, orally administer one dose of a formulation comprising temozolimide to the patient daily, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week, and thereafter (b) do not administer any temozolimide, ABDNAZ, or radiation therapy to the patient for at least two weeks, and thereafter (c) orally administer one dose of a formulation comprising temozolimide to the patient at least 3 days each month, and intravenously administer a formulation comprising ABDNAZ at least once per week.
  • a glioma e.g., a glioblastoma
  • Step No. Dosing Schedule 1 For a duration of at least 3 weeks, orally administer one dose of a formulation comprising temozolimide to the patient daily, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week. 2 After completing step 1, do not administer any temozolimide, ABDNAZ, or radiation therapy to the patient for at least two weeks. 3 After completing step 2, orally administer one dose of a formulation comprising temozolimide to the patient at least 3 days each month, and intravenously administer a formulation comprising ABDNAZ at least once per week.
  • Step No. Dosing Schedule 1 For a duration of at least 3 weeks, orally administer one dose of a formulation comprising temozolimide to the patient daily at a daily dosage of at least 75 mg/m 2 , intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week. 2 After completing step 1, do not administer any temozolimide, ABDNAZ, or radiation therapy to the patient for at least two weeks. 3 After completing step 2, orally administer one dose of a formulation comprising temozolimide to the patient at least 3 days each month, and intravenously administer a formulation comprising ABDNAZ at least once per week.
  • Step No. Dosing Schedule 1 For a duration of at least 6 weeks, orally administer one dose of a formulation comprising temozolimide to the patient daily at a daily dosage of at least 75 mg/m 2 , intravenously administer one dose of a formulation comprising ABDNAZ at least twice once per week wherein each dose of the formulation comprising ABDNAZ provides from about 2.5 mg/m 2 to about 16.5 mg/m 2 of ABDNAZ, and subject the glioma to a dose of radiation therapy at least 5 days each week wherein each dose of radiation therapy provides from about 1 Gy to about 3 Gy of radiation. 2 After completing step 1, do not administer any temozolimide, ABDNAZ, or radiation therapy to the patient for at least four weeks.
  • step 2 After completing step 2, for a duration of at least two months orally administering one dose of a formulation comprising temozolimide to the patient at least 5 days each month wherein each dose of the formulation comprising temozolimide provides from about 150 mg/m 2 to about 200 mg/m 2 of temozolimide, and intravenously administer a dose of a formulation comprising ABDNAZ at least once per week where each dose of the formulation comprising ABDNAZ provides at least 5 mg/m 2 of ABDNAZ.
  • Step No. Dosing Schedule 1 For a duration of at about 6 weeks, orally administer one dose of a formulation comprising temozolimide to the patient daily at a daily dosage of at least 75 mg/m 2 , intravenously administer one dose of a formulation comprising ABDNAZ twice once per week wherein each dose of the formulation comprising ABDNAZ provides from about 2.5 mg/m 2 to about 16.5 mg/m 2 of ABDNAZ, and subject the glioma to a dose of radiation therapy 5 days each week wherein each dose of radiation therapy provides about 2 Gy of radiation. 2 After completing step 1, do not administer any temozolimide, ABDNAZ, or radiation therapy to the patient for about four weeks.
  • step 2 After completing step 2, for a duration of at least two months orally administering one dose of a formulation comprising temozolimide to the patient about 5 days each month wherein each dose of the formulation comprising temozolimide provides from about 150 mg/m 2 to about 200 mg/m 2 of temozolimide, and intravenously administer a dose of a formulation comprising ABDNAZ once per week where each dose of the formulation comprising ABDNAZ provides about 5 mg/m 2 of ABDNAZ.
  • a further exemplary more specific dosing method for treating a glioma is as follows:
  • Another aspect of the invention provides a method of treating a glioma in a patient.
  • the method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
  • Irinotecan is commercially available and marketed in the form of a monohydrochloride trihydrate under the tradename CAMPTOSAR®.
  • the above method may be further characterized by additional features, such as the dosing schedule and amount of irinotecan, dosing schedule of ABDNAZ, dosing amount for ABDNAZ, features of the radiation therapy, and form of irinotecan.
  • the method can be further characterized according to the dosing schedule and amount of the irinotecan. Accordingly, in certain embodiments, the formulation comprising irinotecan is administered at least once per week for a duration of at least 2 weeks. In certain embodiments, the formulation comprising irinotecan is administered at least once per week for a duration of at least 4 weeks.
  • the patient receives the formulation comprising irinotecan by (i) intravenous infusion once weekly at a single dose of at least about 100 mg/m 2 of irinotecan, (ii) intravenous infusion once every two weeks at a single dose of at least about 200 mg/m 2 of irinotecan, or (iii) intravenous infusion once every three weeks at a single dose of at least about 300 mg/m 2 of irinotecan. In certain embodiments, the patient receives the formulation comprising irinotecan by intravenous infusion once weekly at a single dose of about 125 mg/m 2 of irinotecan.
  • a formulation comprising ABDNAZ may be administered multiple times, such as multiple times over a defined period of time. Further, coordination of the dosing schedule of the irinotecan and radiation therapy with that of the formulation comprising ABDNAZ is contemplated to provide therapeutic benefits, such as superior efficacy.
  • two doses of a therapeutically effective amount of a formulation comprising ABDNAZ are administered within about 7 days of administration of the first dose of irinotecan. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of irinotecan, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of irinotecan, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of irinotecan, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of irinotecan, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of 6 weeks following administration of the first dose of irinotecan, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • the patient receives ABDNAZ within about 6 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 24 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 48 hours prior to subjecting the glioma to radiation therapy.
  • the formulation comprising ABDNAZ is administered so that the ABDNAZ exerts physiological activity during an overlapping time period with one or both of the radiation therapy and irinotecan.
  • the dose ABDNAZ described herein for use in combination with irinotecan and radiation therapy has been selected in view of the dosing amount and dosing schedule of the irinotecan and radiation therapy.
  • Dosing amounts of ABDNAZ are provided according to the number of milligrams of ABDNAZ to be administered to the patient based on the surface area of the patient as measured in m 2 .
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2 mg/m 2 to about 20 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2.5 mg/m 2 to about 5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m 2 to about 10 mg/m 2 .
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 10 mg/m 2 to about 16.5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 2.5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 10 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 16.5 mg/m 2 .
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 20 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 10 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.5 mg to about 4.0 mg.
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, or 4.0 mg.
  • the glioma is subjected to radiation therapy once per day for at least 3 days within a 7 day period following administration of the first dose of irinotecan. In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 5 days within a 7 day period following administration of the first dose of irinotecan. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of irinotecan, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of irinotecan, the glioma is subjected to radiation therapy once per day for at least 5 days of each week.
  • the amount of radiation provided to the glioma on the day of administering the radiation therapy is from about 1 Gy to about 3 Gy. In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is about 2 Gy.
  • the glioma is exposed to from about 50 Gy to about 70 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of irinotecan. In certain embodiments, the glioma is exposed to about 60 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of irinotecan.
  • the radiation therapy is (i) conventional fractionated external beam radiation or (ii) intensity-modulated radiation therapy. In certain embodiments, the radiation therapy is (i) conventional fractionated external beam radiation.
  • exemplary types of radiation therapy include, for example, radiation therapy comprising gamma rays, X-rays, electron beams, neutron beams, particulate radiation, proton beams, or the like.
  • the source of the radiation is desirably external to the patient, which involves directing a beam of high-energy radiation to the glioma using a machine external to the patient.
  • the target site i.e., site of the glioma
  • the target site is exposed to the radiation therapy for a short duration of time, such as less than about 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute for each dose of radiation therapy.
  • the method may be further characterized according to the form of irinotecan used, such as a free base or pharmaceutically acceptable salt (such an acid addition salt).
  • irinotecan used, such as a free base or pharmaceutically acceptable salt (such an acid addition salt).
  • the formulation comprising irinotecan comprises irinotecan hydrochloride.
  • a therapeutic method for treating a glioblastoma by administering to a patient in need thereof (a) for a duration of at least 3 weeks, orally administer one dose of a formulation comprising irinotecan to the patient daily, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week, and thereafter (b) do not administer any irinotecan, ABDNAZ, or radiation therapy to the patient for at least two weeks, and thereafter (c) orally administer one dose of a formulation comprising irinotecan to the patient at least 3 days each month, and intravenously administer a formulation comprising ABDNAZ at least once per week.
  • a glioma e.g., a glioblastoma
  • Step No. Dosing Schedule 1 For a duration of at least 2 weeks, intravenously administer one dose of a formulation comprising irinotecan to the patient at least once per week wherein each dose provides at least 100 mg/m 2 of irinotecan, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least once per week. 2 After completing step 1, do not administer any irinotecan to the patient for at least one week.
  • Step No. Dosing Schedule 1 For a duration of at least 4 weeks, intravenously administer one dose of a formulation comprising irinotecan to the patient at least once per week wherein each dose provides at least 100 mg/m 2 of irinotecan, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least twice per week. 2 After completing step 1, do not administer any irinotecan to the patient for at least two weeks.
  • Step No. Dosing Schedule 1 For a duration of at least 2 weeks, intravenously administer one dose of a formulation comprising irinotecan to the patient at least once per week wherein each dose provides at least 125 mg/m 2 of irinotecan, intravenously administer one dose of a formulation comprising ABDNAZ at least twice once per week wherein each dose of the formulation comprising ABDNAZ provides from about 2.5 mg/m 2 to about 16.5 mg/m 2 of ABDNAZ, and subject the glioma to a dose of radiation therapy at least 2 days each week wherein each dose of radiation therapy provides from about 1 Gy to about 3 Gy of radiation. 2 After completing step 1, do not administer any irinotecan for at least one week.
  • Step No. Dosing Schedule 1 For a duration of at least 3 weeks, intravenously administer one dose of a formulation comprising irinotecan to the patient once every three weeks wherein each dose provides at least 350 mg/m 2 of irinotecan, intravenously administer one dose of a formulation comprising ABDNAZ at least twice once per week wherein each dose of the formulation comprising ABDNAZ provides from about 2.5 mg/m 2 to about 16.5 mg/m 2 of ABDNAZ, and subject the glioma to a dose of radiation therapy at least 2 days each week wherein each dose of radiation therapy provides from about 1 Gy to about 3 Gy of radiation. 2 After completing step 1, do not administer any irinotecan for at least two weeks.
  • Another aspect of the invention provides a method of treating a glioma in a patient.
  • the method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising bevacizumab, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the bevacizumab; to treat the glioma.
  • Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems.
  • Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF.
  • Bevacizumab has an approximate molecular weight of 149 kD and can be produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium containing the antibiotic gentamicin. Bevacizumab is marketed commercially as AVASTIN®.
  • bevacizumab marketed commercially as AVASTIN® is a clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion.
  • the formulation is supplied in 100 mg and 400 mg amounts of bevacizumab in preservative-free, single-use vials.
  • the 100 mg product is formulated in 240 mg ⁇ , ⁇ -trehalose dihydrate, 23.2 mg sodium phosphate (monobasic, monohydrate), 4.8 mg sodium phosphate (dibasic, anhydrous), 1.6 mg polysorbate 20, and Water for Injection, USP.
  • the 400 mg product is formulated in 960 mg ⁇ , ⁇ -trehalose dihydrate, 92.8 mg sodium phosphate (monobasic, monohydrate), 19.2 mg sodium phosphate (dibasic, a 695 nhydrous), 6.4 mg polysorbate 20, and Water for Injection, USP.
  • the above method may be further characterized by additional features, such as the dosing schedule and amount of bevacizumab, dosing schedule of ABDNAZ, dosing amount for ABDNAZ, and features of the radiation therapy.
  • the method can be further characterized according to the dosing schedule and amount of the bevacizumab. Accordingly, in certain embodiments, the formulation comprising bevacizumab is administered once every 2 weeks for a duration of at least 4 weeks. In certain embodiments, the formulation comprising bevacizumab is administered once every 3 weeks for a duration of at least 6 weeks.
  • the patient receives the formulation comprising bevacizumab by (i) intravenous infusion once every 2 weeks at a dose of at least about 5 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, (ii) intravenous infusion once every 2 weeks at a dose of at least about 10 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, or (iii) intravenous infusion once every 3 weeks at a dose of at least about 15 mg/kg of bevacizumab for a duration of at least 6, 12, 15, or 18 weeks.
  • the patient receives the formulation comprising bevacizumab by intravenous infusion once every 2 weeks at a dose of 5-10 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks.
  • the patient receives the formulation comprising bevacizumab by (i) intravenous infusion once every 2 weeks at a dose of about 5 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, (ii) intravenous infusion once every 2 weeks at a dose of about 10 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, or (iii) intravenous infusion once every 3 weeks at a dose of about 15 mg/kg of bevacizumab for a duration of at least 6, 12, 15, or 18 weeks.
  • the patient receives the formulation comprising bevacizumab by intravenous infusion once every 2 weeks at a dose of 5-20 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks.
  • a formulation comprising ABDNAZ may be administered multiple times, such as multiple times over a defined period of time. Further, coordination of the dosing schedule of the bevacizumab and radiation therapy with that of the formulation comprising ABDNAZ is contemplated to provide therapeutic benefits, such as superior efficacy.
  • two doses of a therapeutically effective amount of a formulation comprising ABDNAZ are administered within about 7 days of administration of the first dose of bevacizumab. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of bevacizumab, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of bevacizumab, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, the patient receives ABDNAZ within about 6 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 24 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 48 hours prior to subjecting the glioma to radiation therapy.
  • the formulation comprising ABDNAZ is administered so that the ABDNAZ exerts physiological activity during an overlapping time period with one or both of the radiation therapy and bevacizumab.
  • the dose ABDNAZ described herein for use in combination with bevacizumab and radiation therapy has been selected in view of the dosing amount and dosing schedule of the bevacizumab and radiation therapy.
  • Dosing amounts of ABDNAZ are provided according to the number of milligrams of ABDNAZ to be administered to the patient based on the surface area of the patient as measured in m 2 .
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2 mg/m 2 to about 20 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2.5 mg/m 2 to about 5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m 2 to about 10 mg/m 2 .
  • each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 10 mg/m 2 to about 16.5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 2.5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 10 mg/m 2 . In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 16.5 mg/m 2 .
  • the glioma is subjected to radiation therapy once per day for at least 3 days within a 7 day period following administration of the first dose of bevacizumab. In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 5 days within a 7 day period following administration of the first dose of bevacizumab. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of bevacizumab, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of bevacizumab, the glioma is subjected to radiation therapy once per day for at least 5 days of each week.
  • the amount of radiation provided to the glioma on the day of administering the radiation therapy is from about 1 Gy to about 3 Gy. In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is about 2 Gy.
  • the glioma is exposed to from about 50 Gy to about 70 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of bevacizumab. In certain embodiments, the glioma is exposed to about 60 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of bevacizumab.
  • the radiation therapy is (i) conventional fractionated external beam radiation or (ii) intensity-modulated radiation therapy. In certain embodiments, the radiation therapy is (i) conventional fractionated external beam radiation.
  • exemplary types of radiation therapy include, for example, radiation therapy comprising gamma rays, X-rays, electron beams, neutron beams, particulate radiation, proton beams, or the like.
  • the source of the radiation is desirably external to the patient, which involves directing a beam of high-energy radiation to the glioma using a machine external to the patient.
  • the target site i.e., site of the glioma
  • the target site is exposed to the radiation therapy for a short duration of time, such as less than about 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute for each dose of radiation therapy.
  • a therapeutic method for treating a glioblastoma by administering to a patient in need thereof for a duration of at least 3 weeks, orally administer one dose of a formulation comprising bevacizumab to the patient daily, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week.
  • a glioma e.g., a glioblastoma
  • bevacizumab Exemplary more specific illustrations of the contemplated dosing methods for treating a glioma (e.g., a glioblastoma) using bevacizumab are provided below in Table 10 below describing multiple more specific dosing schedules.
  • Dosing Schedule A For a duration of at least 4 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every two weeks wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least once per week.
  • B For a duration of at least 4 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every two weeks wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least twice per week.
  • C For a duration of at least 4 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every two weeks wherein each dose provides at least 10 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least twice per week.
  • D For a duration of at least 6 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every three weeks wherein each dose provides at least 15 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least twice per week.
  • E For a duration of at least 4 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every two weeks wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least twice per week, and subject the glioma to radiation therapy at least twice per week.
  • G For a duration of at least 4 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every two weeks wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least twice per week wherein each dose of the formulation comprising ABDNAZ provides from about 2.5 mg/m 2 to about 16.5 mg/m 2 of ABDNAZ, and subject the glioma to radiation therapy at least twice per week wherein each dose of radiation therapy provides from about 1 Gy to about 3 Gy of radiation.
  • H For a duration of at least 4 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every two weeks wherein each dose provides at least 10 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least twice per week wherein each dose of the formulation comprising ABDNAZ provides from about 2.5 mg/m 2 to about 16.5 mg/m 2 of ABDNAZ, and subject the glioma to radiation therapy at least twice per week wherein each dose of radiation therapy provides from about 1 Gy to about 3 Gy of radiation.
  • I For a duration of at least 6 weeks, intravenously administer one dose of a formulation comprising bevacizumab to the patient once every three weeks wherein each dose provides at least 15 mg/kg of bevacizumab, intravenously administer a formulation comprising ABDNAZ at least twice per week wherein each dose of the formulation comprising ABDNAZ provides from about 2.5 mg/m 2 to about 16.5 mg/m 2 of ABDNAZ, and subject the glioma to radiation therapy at least twice per week wherein each dose of radiation therapy provides from about 1 Gy to about 3 Gy of radiation.
  • the methods may be further characterized according to, for example, the type of glioma, patients for treatment, effects of the treatment, formulation of ABDNAZ, and form of ABDNAZ.
  • the methods may be further characterized according to the nature of the glioma.
  • the glioma is an astrocytoma. In certain embodiments, the glioma is a malignant astrocytoma. In certain embodiments, the glioma is a glioblastoma. In certain embodiments, the glioma is a primary glioblastoma. In certain embodiments, the glioma is a secondary glioblastoma. In certain embodiments, the glioma is a gliosarcoma. In certain embodiments, the glioma is an anaplastic glioma with 1p/19q chromosomes intact. In certain embodiments, the glioma is an anaplastic oligodendroglioma or anaplastic oligoastrocytoma.
  • the therapeutic method may be further characterized according to the patient to be treated.
  • the patient is an adult human. In certain other embodiments, the patient is a pediatric human.
  • the patient has previously undergone surgery to remove at least some glioma tissue. In certain embodiments, the patient has previously undergone surgery, to remove at least some glioma tissue, within six weeks prior to receiving the first dose of temozolomide under the methods described herein using ABDNAZ as part of a combination therapy treatment.
  • the therapeutic method may be further characterized according to the effect of the treatment, such as (i) a reduction in the size of at least one glioma tumors in the patient, and/or (ii) reduction in the number of glioma tumor in the patient.
  • the therapeutic method is characterized by at least a 20% reduction in the size of at least one glioma tumor in the patient. In certain other embodiments, there is at least a 35% reduction in the size of at least one glioma tumor in the patient. In certain other embodiments, there is at least a 50% reduction in the size of at least one glioma tumor in the patient.
  • the method may be further characterized according to the formulation comprising ABDNAZ that is administered to the patient.
  • the formulation comprises ABDNAZ, dimethylacetamide, water, and a polyethylene glycol.
  • the polyethylene glycol has a number-average molecular weight of about 400 g/mol.
  • the patient may be administered a pharmaceutically acceptable salt of ABDNAZ.
  • Another aspect of the invention provides a method for increasing the amount of temozolomide, irinotecan, or bevacizumab in a glioma.
  • the method generally involves administering to a patient having a glioma (i) a formulation comprising temozolomide, irinotecan, or bevacizumab and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the temozolomide, irinotecan, or bevacizumab is present in the patient, in order to increase the amount of the temozolomide, irinotecan, or bevacizumab in the glioma.
  • the method may be characterized according to the percent increase in the amount of temozolomide, irinotecan, or bevacizumab in the glioma relative to the amount of temozolomide, irinotecan, or bevacizumab in the glioma following an identical administration procedure but absent administering said effective amount of a formulation comprising ABDNAZ.
  • one aspect of the invention provides a method of increasing the amount of temozolomide in a glioma, where the method comprises administering to a patient having a glioma (i) a formulation comprising temozolomide and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the temozolomide is present in the patient, in order to increase the amount of the temozolomide in the glioma.
  • Another aspect of the invention provides a method of increasing the amount of irinotecan in a glioma, where the method comprises administering to a patient having a glioma (i) a formulation comprising irinotecan and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the irinotecan is present in the patient, in order to increase the amount of the irinotecan in the glioma.
  • Another aspect of the invention provides a method of increasing the amount of bevacizumab in a glioma, where the method comprises administering to a patient having a glioma (i) a formulation comprising bevacizumab and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the bevacizumab is present in the patient, in order to increase the amount of the bevacizumab in the glioma.
  • each of the foregoing methods may be further characterized according to features described above in connection with the First, Second, and Third Methods. Additionally, the foregoing methods may be further characterized according to the percent increase (e.g., at least a 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or 300% increase) in the amount of temozolomide, irinotecan, or bevacizumab in the glioma relative to the amount of temozolomide, irinotecan, or bevacizumab in the glioma following an identical administration procedure but absent administering said effective amount of a formulation comprising ABDNAZ.
  • percent increase e.g., at least a 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or 300% increase
  • the formulation comprising ABDNAZ is administered within about 4, 6, 8, 10, 12, 14, 16, 18, 20 or 24 hours of administration of a formulation comprising one of temozolomide, irinotecan, or bevacizumab.
  • Another aspect of the invention provides a method of treating a glioma in a patient.
  • the method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising ABDNAZ, and (b) thereafter administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide; to treat the glioma.
  • the method may be further characterized by additional features, such as the dosing schedule and amount of temozolomide, dosing schedule of ABDNAZ, dosing amount for ABDNAZ, and/or any rest period/maintenance period, as described above in connection with the First Method.
  • the invention provides pharmaceutical compositions comprising an active therapeutic agent and one or more pharmaceutically acceptable carriers (additives) and/or diluents.
  • the active therapeutic agent is ABDNAZ, such that the invention provides a pharmaceutical composition comprising ABDNAZ formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
  • the a pharmaceutical composition may comprise ABDNAZ in a therapeutically effective amount.
  • compositions of the present invention may be specially formulated for administration in liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions); and (2) parenteral administration by, for example, subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation.
  • oral administration for example, drenches (aqueous or non-aqueous solutions or suspensions)
  • parenteral administration by, for example, subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation.
  • terapéuticaally-effective amount means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
  • phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
  • Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
  • the effective amount may be less than when the agent is used alone.
  • the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
  • kits for treating a glioma comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma according to procedures described herein, such as (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma.
  • the kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma that comprise (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
  • the term “patient” refers to organisms to be treated by the methods of the present invention.
  • Such organisms are preferably mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably humans.
  • the term “effective amount” refers to the amount of a compound (e.g., a compound of the present invention) sufficient to effect beneficial or desired results.
  • An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
  • treating includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
  • the terms “alleviate” and “alleviating” refer to reducing the severity of the condition, such as reducing the severity by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.
  • composition refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
  • the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
  • the compositions also can include stabilizers and preservatives.
  • stabilizers and adjuvants see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. [1975]).
  • the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof.
  • salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
  • acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
  • Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW4 + , wherein W is C 1-4 alkyl, and the like.
  • alkali metal e.g., sodium
  • alkaline earth metal e.g., magnesium
  • W is C 1-4 alkyl
  • salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate,
  • salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
  • salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
  • compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
  • compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.
  • Example 1 Treatment of Human Patients Suffering from a Glioblastoma or Malignant Glioma
  • Patients are to receive oral temozolomide 75 mg/m 2 daily for 6 weeks and undergo conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) 5 days a week for 6 weeks. Patients are also to receive ABDNAZ by intravenous administration twice weekly for 6 weeks administered at one of four dose levels (2.0 mg/m 2 , 8 mg/m 2 , 17 mg/m 2 , or 29 mg/m 2 ) beginning concurrently with temozolomide and radiotherapy. Cohorts of 3-6 patients will receive escalating doses of ABDNAZ until the maximum feasible dose (MFD) or maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 subjects experience dose-limiting toxicity.
  • MTD maximum feasible dose
  • MTD maximum tolerated dose
  • patients are to receive oral temozolomide [150 mg/m 2 orally daily for 5 days during cycle 1 (28 days) and 200 mg/m 2 orally daily for 5 days every 28 days for cycles 2-6] and once weekly ABDNAZ at 2 mg/m 2 on days 1-28. Treatment will repeat every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
  • Patients may be evaluated using the following criteria prior to treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
  • Patients may be evaluated using the following criteria during treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
  • Patients may be evaluated using the following criteria after treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
  • temozolomide is to be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m 2 for a maximum of 49 days (to allow for treatments interruptions, for example, over holidays).
  • the drug will be administered at night just before bedtime.
  • the dose will be determined using actual body surface area (BSA) as defined by the method of DuBois and DuBois.
  • BSA body surface area
  • Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg.
  • the daily dose is to be rounded to the nearest 5 mg. Patients are to be instructed to swallow the capsules whole, in rapid succession, without chewing them.
  • Radiotherapy 2 Gy of radiation is to be given daily 5 days per week for a total of 60 Gy over 6 weeks. All fields shall be treated during each treatment session. Doses are specified such that at least 95% of the planning treatment volume (PTV) shall receive 100% of the prescribed dose; Dose Volume Histograms (DVHs) may be necessary to make this selection. Radiation therapy will be delivered using standard dose and fractionation as described below:
  • Example 2 Treatment of Human Patients Suffering from a Glioblastoma or Malignant Glioma
  • gliobastoma or malignant glioma are to be treated using a combination of ABDNAZ (by intravenous administration at a dose ranging from 0.5 mg to 4.0 mg), temozolomide, and radiation therapy (RT) according to the treatment protocol described below.
  • ABDNAZ by intravenous administration at a dose ranging from 0.5 mg to 4.0 mg
  • temozolomide temozolomide
  • RT radiation therapy
  • Patients are to receive oral temozolomide 75 mg/m 2 daily for 6 weeks and undergo conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) 5 days a week for 6 weeks. Patients are also to receive ABDNAZ by intravenous administration once weekly for 6 weeks administered at one of four dose levels (0.5 mg, 1.0 mg, 2.0 mg, or 4.0 mg) beginning concurrently with temozolomide and radiotherapy. Cohorts of 3-6 patients will receive escalating doses of ABDNAZ until the maximum feasible dose (MFD) or maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 subjects experience dose-limiting toxicity. Administration of temozolomide is no sooner than 4 hours after administration of ABDNAZ. ABDNAZ is preferably administered within three hours prior to administration of radiation therapy.
  • patients are to receive oral temozolomide [150 mg/m 2 orally daily for on days 1-5 during cycle 1 (28 days) and 200 mg/m 2 orally daily on days 1-5 during cycles 2-6 (where each cycle is 28 days)] and once weekly ABDNAZ by intravenous administration at a dose ranging from 0.5 mg to 4.0 mg for six months.
  • Administration of temozolomide is no sooner than 4 hours after administration of ABDNAZ.
  • Patients are to be evaluated by a neuro-oncologist, radiation oncologist, or medical oncologist prior to the start of any treatment. Efficacy of the therapy may be evaluated according to procedure described below.
  • Patients may be evaluated using the following criteria prior to treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
  • Patients may be evaluated using the following criteria during treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
  • Patients may be evaluated using the following criteria after treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
  • temozolomide is to be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m 2 for a maximum of 49 days (to allow for treatments interruptions, for example, over holidays).
  • the drug will be administered at night just before bedtime.
  • the dose will be determined using actual body surface area (BSA) as defined by the method of DuBois and DuBois.
  • BSA body surface area
  • Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg.
  • the daily dose is to be rounded to the nearest 5 mg. Patients are to be instructed to swallow the capsules whole, in rapid succession, without chewing them.
  • Radiotherapy 2 Gy of radiation is to be given daily 5 days per week for a total of 60 Gy over 6 weeks. All fields shall be treated during each treatment session. Doses are specified such that at least 95% of the planning treatment volume (PTV) shall receive 100% of the prescribed dose; Dose Volume Histograms (DVHs) may be necessary to make this selection. Radiation therapy will be delivered using standard dose and fractionation as described below:
  • Example 3 administering ABDNAZ and Temozolomide to a GBM14 TMZ-S Patient-Derived Cell Line and a GBM14 TMZ-R Patient-Derived Cell Line
  • Temozolomide-sensitive human GBM14 (GBM14 TMZ-S) patient derived cell line cells were treated with one of the following (i) ABDNAZ, (ii) temozolomide, or (iii) ABDNAZ and temozolomide.
  • temozolomide-resistant human GBM14 (GBM14 TMZ-R) patient derived cell line cells were treated with one of the following (i) ABDNAZ, (ii) temozolomide, or (iii) ABDNAZ and temozolomide.
  • Experimental procedures and results are provided below.
  • temozolomide-sensitive human GBM14 (GBM14 TMZ-S) patient derived cell line cells were treated with one of the following (i) ABDNAZ at a concentration of 2 ⁇ M, (ii) temozolomide at a concentration of 100 ⁇ M, or (iii) ABDNAZ (at a concentration of 2 ⁇ M) and temozolomide (at a concentration of 100 ⁇ M).
  • WST-1 assay was used to assess the effect of treatment on cell viability over the time of three days. The presence of live cells is detected by absorbance at 440 nm in the assay. Data are presented as the mean ⁇ 3 standard deviations from three separate performances of the experiment.
  • temozolomide-resistant human GBM14 (GBM14 TMZ-R) patient derived cell line cells were treated with one of the following (i) ABDNAZ at a concentration of 2 ⁇ M, (ii) temozolomide at a concentration of 100 ⁇ M, or (iii) ABDNAZ (at a concentration of 2 ⁇ M) and temozolomide (at a concentration of 100 ⁇ M).
  • the presence of live cells is detected by absorbance at 440 nm in the assay.
  • WST-1 assay was used to assess the effect of treatment on cell viability over the time of three days. Data are presented as the mean ⁇ 3 standard deviations from three separate performances of the experiment.
  • Results are presented in FIG. 1 showing response from the GBM14 TMZ-S patient derived cell line and FIG. 2 showing response from the GBM14 TMZ-R patient derived cell line.
  • administration of ABDNAZ and temozolomide together produced a greater amount of cell death as measured by lack of absorbance at 440 nm.
  • NSCG temozolomide-resistant murine EGFRvIII/Arfko neural stem cell-derived glioma
  • NSCG temozolomide-resistant murine EGFRvIII/Arfko neural stem cell-derived glioma
  • Results are presented in FIG. 3 , where the data indicate that administration of ABDNAZ and temozolomide together produced a greater amount of cell death as measured by lack of absorbance at 440 nm. Data are presented as the mean ⁇ 3 standard deviations from three separate performances of the assay.
  • mice implanted with temozolomide-resistant EGFRvIII/Arfko GBM (NSCG) cells were treated with (i) ABDNAZ (RRx-001, 10 mg/kg, intraperitoneal injection), (ii) temozolomide (TMZ)(40 mg/kg, oral gavage), or (iii) ABDNAZ (10 mg/kg, intraperitoneal injection) and temozolomide (40 mg/kg, oral gavage).
  • ABDNAZ RRx-001, 10 mg/kg, intraperitoneal injection
  • TMZ temozolomide
  • TMZ temozolomide
  • ABDNAZ 10 mg/kg, intraperitoneal injection
  • temozolomide 40 mg/kg, oral gavage
  • NSCG tumors were intracranially injected into FVBN mice.
  • Mice to be treated were treated with one of the following (i) ABDNAZ (10 mg/kg, intraperitoneal injection), (ii) temozolomide (40 mg/kg, oral gavage), or (iii) ABDNAZ (10 mg/kg, intraperitoneal injection) and temozolomide (40 mg/kg, oral gavage).
  • treatment i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide
  • the control population of mice contained ten mice, the group receiving only ABDNAZ had twelve mice, the group receiving only temozolomide had twelve mice, and the group receiving both ABDNAZ and temozolomide had sixteen mice.
  • Mouse survival was monitored over time.
  • FIG. 4 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started five days after intracranial injection of NSCG cells.
  • treatment i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide
  • CTL control subjects.
  • Table 1 shows median survival time (in days) observed in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started five days after intracranial injection of NSCG cells.
  • FIG. 5 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started ten days after intracranial injection of NSCG cells.
  • treatment i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide
  • CTL control subjects.
  • Table 2 shows median survival time (in days) observed in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started ten days after intracranial injection of NSCG cells.
  • mice implanted with TMZ-resistant EGFRvIII/Arfko GBM tumors were treated with ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide.
  • ABDNAZ RNTI-001
  • TMZ temozolomide
  • NSCG tumors were orthotopically implanted in FVBN mice. Then, the mice were treated with one of the following (i) ABDNAZ (10 mg/kg, intraperitoneal injection), (ii) temozolomide (40 mg/kg, oral gavage), or (iii) ABDNAZ (10 mg/kg, intraperitoneal injection) and temozolomide (40 mg/kg, oral gavage). Percent apoptosis of CC3+ cells was evaluated.
  • the amount of CC3+ cell apoptosis detected in the assay is shown in FIG. 6 .
  • administration of ABDNAZ and temozolomide together produced the highest percentage of CC3+ cell apoptosis.
  • the abbreviation “CTL” refers to control mice; the symbol *** refers to p ⁇ 0.001.
  • Example 7 administering of ABDNAZ and Temozolomide to Mice Implanted with Brain Tumors
  • mice implanted with brain tumors were treated with ABDNAZ, temozolomide (TMZ), or both ABDNAZ and temozolomide. Experimental procedures and results are provided below.
  • mice Brain tumors were orthotopically implanted in the brain of mice. Then, the mice were treated with one of the following (i) ABDNAZ, (ii) temozolomide, or (iii) ABDNAZ followed by administration of temozolomide 4 hours later.
  • ABDNAZ (10 mg/kg) was administered via tail vein 4 hours before any temozolomide (20 mg/kg) via tail vein once weekly for 4 weeks. Twenty-four hours after temozolomide administration, tumor-bearing mice were euthanized and brain tumor tissue was collected and dissected. Temozolomide levels in tumor tissues were measured.
  • TMZ temozolomide
  • Example 8 administering of ABDNAZ and Irinotecan to Mice Implanted with Human Glioblastoma GBM43 Brain Tumors
  • mice implanted with human glioblastoma GBM43 brain tumors were treated with ABDNAZ, irinotecan, or both ABDNAZ and irinotecan. Experimental procedures and results are provided below.
  • mice Human glioblastoma GBM43 tumors were orthotopically implanted in the brain of immunocompromised mice. Then, the mice were treated with one of the following (i) ABDNAZ, (ii) irinotecan, or (iii) ABDNAZ followed by administration of irinotecan 4 hours later. Twenty-four hours after irinotecan administration, tumor-bearing mice were euthanized and brain tumor tissue was collected and dissected. Irinotecan levels in tumor tissues were measured.
  • the concentration of irinotecan detected in brain tumor tissue of the mice is shown in FIG. 8 .
  • administration of ABDNAZ prior to administration of irinotecan resulted in a greater concentration of irinotecan in the brain tumor tissue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)

Abstract

The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application is a continuation patent application under 35 U.S.C. § 120 of U.S. patent application Ser. No. 15/989,862, filed on May 25, 2018, which is a continuation patent application of U.S. patent application Ser. No. 15/337,378, filed on Oct. 28, 2016, which claims the benefit of and priority to U.S. Provisional Patent Application No. 62/247,846, filed on Oct. 29, 2015, the contents of each of which are hereby incorporated by reference herein, in their entirety.
    • FIELD OF THE INVENTION
  • The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
    • BACKGROUND
  • Gliomas are tumors that arise from glial tissue of the brain. Gliomas are often found in the cerebral hemispheres of the brain, but can be found anywhere in the brain. Because gliomas can grow rapidly, common symptoms experienced by patients suffering from a glioma are often associated with an increased pressure in the brain. The symptoms can include headache, nausea, vomiting, and drowsiness. In addition, patients suffering from a glioma may develop other symptoms such as weakness on one side of the body, memory and/or speech difficulties, and visual changes, often as function of the location of the glioma tumor.
  • Gliomas can be characterized according to grade, where low-grade gliomas [WHO grade II] are typically well-differentiated and tend to exhibit benign tendencies. Low-grade gliomas stand in contrast to high-grade gliomas [WHO grade III or IV] that are typically undifferentiated and frequently malignant. One example of a high-grade glioma is glioblastoma multiforme. Glioblastoma multiforme has been characterized as a World Health Organization grade IV astrocytoma, with an incidence in North America of 5.0 per 100,000 in the population, representing 15 to 20% of all primary intracranial neoplasms.
  • Currently available therapeutic approaches for treating patients suffering from a glioma include surgery, radiation therapy, and treatment with certain anti-cancer agents. A typical first step in treating a glioblastoma is to surgically remove as much tumor as possible. This can help alleviate pressure on the brain. However, glioblastomas often have finger-like tentacles, and as a result it can be difficult to completely remove all the glioblastoma. This is particularly true when a glioblastoma appears near parts of the brain that control important functions, such as language and coordination. Radiation and chemotherapy may be used to help slow the growth of glioblastoma tumors that cannot be removed with surgery. However, survival rates are low using current standard treatments for glioblastoma. For example, using standard treatments currently approved by government regulatory agencies, the median survival time for adults with an anaplastic astrocytoma has been reported to be about two to three years. For children suffering from a high-grade glioma tumor (grade III or IV), the five-year survival rate has been reported to be about twenty-five percent.
  • As a result, there is a need for additional therapies to treat patients suffering from a glioma. The present invention addresses this need and provides other related advantages.
    • SUMMARY
  • The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab. The compound ABDNAZ has the following chemical structure:
  • Figure US20200375982A1-20201203-C00001
  • The therapeutic methods and kits provide a solution to the long unmet need for a more effective treatment for patients suffering from a glioma. The therapeutic method generally entails (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, irinotecan, or bevacizumab, and within a certain amount of time (e.g., about 7 days) subjecting the glioma to radiation therapy, and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide, irinotecan, or bevacizumab, in order to treat the glioma. In preferred embodiments, the radiation therapy may be administered to the patient for a select number of days (e.g., at least 2, 3, 4, or 5 days) over a two-week period, or longer duration of time depending on patient response to the therapy. In preferred embodiments, the formulation comprising ABDNAZ may be administered to the patient for a select number of days per week (e.g., at least 2, 3, or 4 days per week) over a two-week period, or longer duration of time depending on patient response to the therapy. The therapy may be used to treat various types of gliomas, such as, for example, a primary glioblastoma or a secondary glioblastoma. The invention having been generally described is explained in more detail in the aspects and embodiments below and in the detailed description.
  • Accordingly, one aspect of the invention provides a method of treating a glioma in a patient. The method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma.
  • Another aspect of the invention provides a method of treating a glioma in a patient. The method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
  • Another aspect of the invention provides a method of treating a glioma in a patient. The method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising bevacizumab, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the bevacizumab; to treat the glioma.
  • Another aspect of the invention provides a kit for treating a glioma. In certain embodiments, the kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma according to procedures described herein, such as (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma. In an alternative embodiment, the kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma that comprise (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a graph showing response observed using a GBM14 TMZ-S patient-derived cell line, as described in Example 3.
  • FIG. 2 is a graph showing response observed using a GBM14 TMZ-R patient-derived cell line, as described in Example 3.
  • FIG. 3 is a graph showing response observed using cells from temozolomide-resistant murine EGFRvIII/Arfko neural stem cell-derived glioma (NSCG) cell line, as described in Example 4.
  • FIG. 4 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started five days after intracranial injection of NSCG cells, as described in Example 5.
  • FIG. 5 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started ten days after intracranial injection of NSCG cells, as described in Example 5.
  • FIG. 6 is a graph showing the amount of CC3+ cell apoptosis detected in the assay, as described in Example 6.
  • FIG. 7 is a graph showing the amount of TMZ (mg) detected per gram of tissue analyzed, as described in Example 7.
  • FIG. 8 is a graph showing the amount of irinotecan (μg) detected per milligram of tissue analyzed, as described in Example 8.
    •  DETAILED DESCRIPTION
  • The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab. The compound ABDNAZ has the following chemical structure:
  • Figure US20200375982A1-20201203-C00002
  • The therapeutic methods and kits provide a solution to the long unmet need for a more effective treatment for patients suffering from a glioma. The therapeutic method generally entails (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, irinotecan, or bevacizumab, and within a certain amount of time (e.g., about 7 days) subjecting the glioma to radiation therapy, and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide, irinotecan, or bevacizumab, in order to treat the glioma. In preferred embodiments, the radiation therapy may be administered to the patient for a select number of days (e.g., at least 2, 3, 4, or 5 days) over a two-week period, or longer duration of time depending on patient response to the therapy. In preferred embodiments, the formulation comprising ABDNAZ may be administered to the patient for a select number of days per week (e.g., at least 2, 3, or 4 days per week) over a two-week period, or longer duration of time depending on patient response to the therapy. The therapy may be used to treat various types of gliomas, such as, for example, a primary glioblastoma or a secondary glioblastoma.
  • Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section.
    • I. Therapeutic Methods for Treating a Glioma
  • The invention provides therapeutic methods for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab. The therapeutic methods provide a solution to the long unmet need for a more effective treatment for patients suffering from a glioma. The therapeutic method generally entails (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, irinotecan, or bevacizumab, and within a certain amount of time (e.g., about 7 days) subjecting the glioma to radiation therapy, and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide, irinotecan, or bevacizumab, in order to treat the glioma.
  • The invention also provides methods for increasing the amount of temozolomide, irinotecan, or bevacizumab in a glioma. The method generally involves administering to a patient having a glioma (i) a first formulation comprising temozolomide, irinotecan, or bevacizumab and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the temozolomide, irinotecan, or bevacizumab is present in the patient, in order to increase the amount of the temozolomide, irinotecan, or bevacizumab in the glioma.
  • Various features of the methods are described in sections below. The sections are arranged for convenience and information in one section is not limited to that section, but may be applied to other sections.
    • First Method—Using Temozolomide
  • One aspect of the invention provides a method of treating a glioma in a patient. The method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma.
  • Temozolomide is a small molecule having the chemical name 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide, which is marketed commercially under the tradename TEMODAR®.
    • Exemplary Features of the Method
  • The above method may be further characterized by additional features, such as the dosing schedule and amount of temozolomide, dosing schedule of ABDNAZ, dosing amount for ABDNAZ, features of the radiation therapy, and the rest period/maintenance period.
    • Dosing Schedule and Amount of Temozolomide
  • The method can be further characterized according to the dosing schedule and amount of the temozolomide. Accordingly, in certain embodiments, the formulation comprising temozolomide is administered daily for at least 2 weeks. In certain embodiments, the formulation comprising temozolomide is administered daily for at least 4 weeks. In certain embodiments, the formulation comprising temozolomide is administered daily for at least 6 weeks. In certain embodiments, the formulation comprising temozolomide is administered at the patient's bedtime.
  • In certain embodiments, the patient receives temozolomide by oral administration at a daily dose of at least 50 mg/m2. In certain embodiments, the patient receives temozolomide by oral administration at a daily dose of about 50 mg/m2 to about 100 mg/m2. In certain embodiments, the patient receives temozolomide by oral administration at a daily dose of about 75 mg/m2.
    • Dosing Schedule of ABDNAZ
  • A formulation comprising ABDNAZ may be administered multiple times, such as multiple times over a defined period of time. Further, coordination of the dosing schedule of the temozolomide and radiation therapy with that of the formulation comprising ABDNAZ is contemplated to provide therapeutic benefits, such as superior efficacy.
  • In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of temozolomide, the patient receives at least one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of temozolomide, the patient receives at least one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the patient receives at least one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, two doses of a therapeutically effective amount of a formulation comprising ABDNAZ are administered within about 7 days of administration of the first dose of temozolomide. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of temozolomide, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of temozolomide, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of temozolomide, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of temozolomide, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of 6 weeks following administration of the first dose of temozolomide, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • In certain embodiments, any dose of ABDNAZ administered to the patient within 12 hours of administering temozolomide is administered at least 3 hours before administering the temozolomide.
  • In certain embodiments, the patient receives ABDNAZ within about 3 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 6 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 24 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 48 hours prior to subjecting the glioma to radiation therapy.
  • In certain embodiments, the formulation comprising ABDNAZ is administered so that the ABDNAZ exerts physiological activity during an overlapping time period with one or both of the radiation therapy and temozolomide.
    • Dosing Amount of ABDNAZ
  • The method may be further a characterized according to the dose of ABDNAZ administered to the patient. The dose of ABDNAZ described herein for use in combination with temozolomide and the radiation therapy has been selected in view of the dosing schedule and amount of temozolomide and the radiation therapy. Dosing amounts of ABDNAZ are provided according to the number of milligrams of ABDNAZ to be administered to the patient based on the surface area of the patient as measured in m2.
  • In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2 mg/m2 to about 20 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2.5 mg/m2 to about 5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m2 to about 10 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 10 mg/m2 to about 16.5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 2.5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 10 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 16.5 mg/m2.
  • In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 20 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 10 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.5 mg to about 4.0 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, or 4.0 mg.
    • Radiation Therapy Features
  • The method can be further characterized according to the dosing schedule and amount of radiation administered for the radiation therapy.
  • In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 3 days within a 7 day period following administration of the first dose of temozolomide. In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 5 days within a 7 day period following administration of the first dose of temozolomide. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 3 days of each week. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 3 days of each week. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 3 days of each week. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for 5 days each week. In certain embodiments, for a duration of 6 weeks following administration of the first dose of temozolomide, the glioma is subjected to radiation therapy once per day for 5 days each week.
  • In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is from about 1 Gy to about 3 Gy. In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is about 2 Gy. In certain embodiments, the glioma is exposed to from about 50 Gy to about 70 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of temozolomide. In certain embodiments, the glioma is exposed to about 60 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of temozolomide.
  • In certain embodiments, the radiation therapy is (i) conventional fractionated external beam radiation or (ii) intensity-modulated radiation therapy. In certain embodiments, the radiation therapy is conventional fractionated external beam radiation.
  • Various types of radiation therapy are used by those skilled in the art and have been described in the literature. Exemplary types of radiation therapy include, for example, radiation therapy comprising gamma rays, X-rays, electron beams, neutron beams, particulate radiation, proton beams, or the like. The source of the radiation is desirably external to the patient, which involves directing a beam of high-energy radiation to the glioma using a machine external to the patient. Desirably the target site (i.e., site of the glioma) is exposed to the radiation therapy for a short duration of time, such as less than about 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute for each dose of radiation therapy.
    • Rest Period/Maintenance Period
  • The method may be further characterized according to the scope of the rest period/maintenance period. For example, in certain embodiments, after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks.
  • In certain embodiments, the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least three days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least two weeks. In certain embodiments, the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 1 month. In certain embodiments, the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five consecutive days during the first week of each 28 day period, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 4 months. In certain embodiments, after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks. In certain embodiments, the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least three days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least two weeks. In certain embodiments, the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five days during the first week, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 1 month. In certain embodiments, the patient after having not received any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks, then receives (i) a therapeutically effective amount of a formulation comprising temozolomide on at least five consecutive days during the first week of each 28 day period, and (ii) a therapeutically effective amount of a formulation comprising ABDNAZ at least once per week for a duration of at least 4 months.
  • In certain embodiments, after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of about 3 weeks to about 6 weeks.
  • In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of at least 150 mg/m2. In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m2. In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of from about 75 mg/m2 to about 400 mg/m2. In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of from about 150 mg/m2 to about 350 mg/m2. In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising temozolomide is administered orally to the patient to provide temozolomide in an amount of about 150 mg/m2, 200 mg/m2, 250 mg/m2, 300 mg/m2, or 350 mg/m2.
  • In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 10 mg. In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.5 mg to about 4.0 mg. In certain embodiments, after the duration over which the patient has not received any of temozolomide, radiation therapy, or ABDNAZ, the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 0.5 mg, 1.0 mg, 1.5, mg, 2.0 mg, 2.5 mg, 3.0 mg, or 4.0 mg.
    • Combinations of Embodiments and Illustration of Exemplary More Specific Methods
  • All combinations of aspects and embodiments described above are contemplated. For example, a therapeutic method is contemplated for treating a glioblastoma by administering to a patient in need thereof (a) for a duration of at least 3 weeks, orally administer one dose of a formulation comprising temozolimide to the patient daily, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week, and thereafter (b) do not administer any temozolimide, ABDNAZ, or radiation therapy to the patient for at least two weeks, and thereafter (c) orally administer one dose of a formulation comprising temozolimide to the patient at least 3 days each month, and intravenously administer a formulation comprising ABDNAZ at least once per week.
  • Exemplary more specific illustrations of the contemplated dosing methods for treating a glioma (e.g., a glioblastoma) are provided below in Tables 1, 2, 3, and 4.
  • TABLE 1
    Step No. Dosing Schedule
    1 For a duration of at least 3 weeks, orally administer one dose of a
    formulation comprising temozolimide to the patient daily, intravenously
    administer a formulation comprising ABDNAZ at least once per week, and
    subject the glioma to radiation therapy at least 3 days each week.
    2 After completing step 1, do not administer any temozolimide, ABDNAZ, or
    radiation therapy to the patient for at least two weeks.
    3 After completing step 2, orally administer one dose of a formulation
    comprising temozolimide to the patient at least 3 days each month, and
    intravenously administer a formulation comprising ABDNAZ at least once
    per week.
  • TABLE 2
    Step No. Dosing Schedule
    1 For a duration of at least 3 weeks, orally administer one dose of a
    formulation comprising temozolimide to the patient daily at a daily dosage
    of at least 75 mg/m2, intravenously administer a formulation comprising
    ABDNAZ at least once per week, and subject the glioma to radiation therapy
    at least 3 days each week.
    2 After completing step 1, do not administer any temozolimide, ABDNAZ, or
    radiation therapy to the patient for at least two weeks.
    3 After completing step 2, orally administer one dose of a formulation
    comprising temozolimide to the patient at least 3 days each month, and
    intravenously administer a formulation comprising ABDNAZ at least once
    per week.
  • TABLE 3
    Step No. Dosing Schedule
    1 For a duration of at least 6 weeks, orally administer one dose of a
    formulation comprising temozolimide to the patient daily at a daily dosage
    of at least 75 mg/m2, intravenously administer one dose of a formulation
    comprising ABDNAZ at least twice once per week wherein each dose of the
    formulation comprising ABDNAZ provides from about 2.5 mg/m2 to about
    16.5 mg/m2 of ABDNAZ, and subject the glioma to a dose of radiation
    therapy at least 5 days each week wherein each dose of radiation therapy
    provides from about 1 Gy to about 3 Gy of radiation.
    2 After completing step 1, do not administer any temozolimide, ABDNAZ, or
    radiation therapy to the patient for at least four weeks.
    3 After completing step 2, for a duration of at least two months orally
    administering one dose of a formulation comprising temozolimide to the
    patient at least 5 days each month wherein each dose of the formulation
    comprising temozolimide provides from about 150 mg/m2 to about 200
    mg/m2 of temozolimide, and intravenously administer a dose of a
    formulation comprising ABDNAZ at least once per week where each dose
    of the formulation comprising ABDNAZ provides at least 5 mg/m2 of
    ABDNAZ.
  • TABLE 4
    Step No. Dosing Schedule
    1 For a duration of at about 6 weeks, orally administer one dose of a
    formulation comprising temozolimide to the patient daily at a daily dosage
    of at least 75 mg/m2, intravenously administer one dose of a formulation
    comprising ABDNAZ twice once per week wherein each dose of the
    formulation comprising ABDNAZ provides from about 2.5 mg/m2 to about
    16.5 mg/m2 of ABDNAZ, and subject the glioma to a dose of radiation
    therapy 5 days each week wherein each dose of radiation therapy provides
    about 2 Gy of radiation.
    2 After completing step 1, do not administer any temozolimide, ABDNAZ, or
    radiation therapy to the patient for about four weeks.
    3 After completing step 2, for a duration of at least two months orally
    administering one dose of a formulation comprising temozolimide to the
    patient about 5 days each month wherein each dose of the formulation
    comprising temozolimide provides from about 150 mg/m2 to about 200
    mg/m2 of temozolimide, and intravenously administer a dose of a
    formulation comprising ABDNAZ once per week where each dose of the
    formulation comprising ABDNAZ provides about 5 mg/m2 of ABDNAZ.
  • A further exemplary more specific dosing method for treating a glioma (e.g., a glioblastoma) is as follows:
      • Step 1: for a duration of at about 6 weeks, orally administer one dose of a formulation comprising temozolimide to the patient daily at a daily dosage of about 75 mg/m2, intravenously administer one dose of a formulation comprising ABDNAZ once per week wherein each dose of the formulation comprising ABDNAZ provides from about 0.5 mg to about 4.0 mg of ABDNAZ, and subject the glioma to a dose of radiation therapy 5 days each week wherein each dose of radiation therapy provides about 2 Gy of radiation. The ABDNAZ is administered within 3 hours prior to administering radiation therapy, and the temozolomide is administered no sooner than 3 hours after administering the ABDNAZ.
      • Step 2: after completing step 1, do not administer any temozolimide, ABDNAZ, or radiation therapy to the patient for about three to six weeks.
      • Step 3: after completing step 2, for a duration of at least five months (preferably for six months) orally administer one dose of a formulation comprising temozolimide to the patient about 5 days each month (e.g., days 1-5 of each month) wherein each dose of the formulation comprising temozolimide provides from about 150 mg/m2 to about 350 mg/m2 of temozolimide, and intravenously administer one dose of a formulation comprising ABDNAZ once per week where each dose of the formulation comprising ABDNAZ provides about from about 0.5 mg to about 4.0 mg of ABDNAZ.
    Second Method—Using Irinotecan
  • Another aspect of the invention provides a method of treating a glioma in a patient. The method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
  • Irinotecan is commercially available and marketed in the form of a monohydrochloride trihydrate under the tradename CAMPTOSAR®.
    • Exemplary Features of the Method
  • The above method may be further characterized by additional features, such as the dosing schedule and amount of irinotecan, dosing schedule of ABDNAZ, dosing amount for ABDNAZ, features of the radiation therapy, and form of irinotecan.
    • Dosing Schedule and Amount of Irinotecan
  • The method can be further characterized according to the dosing schedule and amount of the irinotecan. Accordingly, in certain embodiments, the formulation comprising irinotecan is administered at least once per week for a duration of at least 2 weeks. In certain embodiments, the formulation comprising irinotecan is administered at least once per week for a duration of at least 4 weeks.
  • In certain embodiments, the patient receives the formulation comprising irinotecan by (i) intravenous infusion once weekly at a single dose of at least about 100 mg/m2 of irinotecan, (ii) intravenous infusion once every two weeks at a single dose of at least about 200 mg/m2 of irinotecan, or (iii) intravenous infusion once every three weeks at a single dose of at least about 300 mg/m2 of irinotecan. In certain embodiments, the patient receives the formulation comprising irinotecan by intravenous infusion once weekly at a single dose of about 125 mg/m2 of irinotecan.
    • Dosing Schedule for ABDNAZ
  • A formulation comprising ABDNAZ may be administered multiple times, such as multiple times over a defined period of time. Further, coordination of the dosing schedule of the irinotecan and radiation therapy with that of the formulation comprising ABDNAZ is contemplated to provide therapeutic benefits, such as superior efficacy.
  • In certain embodiments, two doses of a therapeutically effective amount of a formulation comprising ABDNAZ are administered within about 7 days of administration of the first dose of irinotecan. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of irinotecan, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of irinotecan, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of irinotecan, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of irinotecan, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 6 weeks following administration of the first dose of irinotecan, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of 6 weeks following administration of the first dose of irinotecan, the patient receives one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
  • In certain embodiments, the patient receives ABDNAZ within about 6 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 24 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 48 hours prior to subjecting the glioma to radiation therapy.
  • In certain embodiments, the formulation comprising ABDNAZ is administered so that the ABDNAZ exerts physiological activity during an overlapping time period with one or both of the radiation therapy and irinotecan.
    • Dose of ABDNAZ Administered
  • The dose ABDNAZ described herein for use in combination with irinotecan and radiation therapy has been selected in view of the dosing amount and dosing schedule of the irinotecan and radiation therapy. Dosing amounts of ABDNAZ are provided according to the number of milligrams of ABDNAZ to be administered to the patient based on the surface area of the patient as measured in m2.
  • In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2 mg/m2 to about 20 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2.5 mg/m2 to about 5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m2 to about 10 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 10 mg/m2 to about 16.5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 2.5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 10 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 16.5 mg/m2.
  • In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 20 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 10 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.5 mg to about 4.0 mg. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, or 4.0 mg.
    • Radiation Therapy Features
  • In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 3 days within a 7 day period following administration of the first dose of irinotecan. In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 5 days within a 7 day period following administration of the first dose of irinotecan. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of irinotecan, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of irinotecan, the glioma is subjected to radiation therapy once per day for at least 5 days of each week.
  • In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is from about 1 Gy to about 3 Gy. In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is about 2 Gy.
  • In certain embodiments, the glioma is exposed to from about 50 Gy to about 70 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of irinotecan. In certain embodiments, the glioma is exposed to about 60 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of irinotecan.
  • In certain embodiments, the radiation therapy is (i) conventional fractionated external beam radiation or (ii) intensity-modulated radiation therapy. In certain embodiments, the radiation therapy is (i) conventional fractionated external beam radiation.
  • Various types of radiation therapy are used by those skilled in the art and have been described in the literature. Exemplary types of radiation therapy include, for example, radiation therapy comprising gamma rays, X-rays, electron beams, neutron beams, particulate radiation, proton beams, or the like. The source of the radiation is desirably external to the patient, which involves directing a beam of high-energy radiation to the glioma using a machine external to the patient. Desirably the target site (i.e., site of the glioma) is exposed to the radiation therapy for a short duration of time, such as less than about 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute for each dose of radiation therapy.
    • Form of Irinotecan
  • The method may be further characterized according to the form of irinotecan used, such as a free base or pharmaceutically acceptable salt (such an acid addition salt). In certain embodiments, the formulation comprising irinotecan comprises irinotecan hydrochloride.
    • Combinations of Embodiments and Illustration of Exemplary More Specific Methods
  • All combinations of aspects and embodiments described above are contemplated. For example, a therapeutic method is contemplated for treating a glioblastoma by administering to a patient in need thereof (a) for a duration of at least 3 weeks, orally administer one dose of a formulation comprising irinotecan to the patient daily, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week, and thereafter (b) do not administer any irinotecan, ABDNAZ, or radiation therapy to the patient for at least two weeks, and thereafter (c) orally administer one dose of a formulation comprising irinotecan to the patient at least 3 days each month, and intravenously administer a formulation comprising ABDNAZ at least once per week.
  • Exemplary more specific illustrations of the contemplated dosing methods for treating a glioma (e.g., a glioblastoma) are provided below in Tables 5, 6, 7, 8, and 9.
  • TABLE 5
    Step No. Dosing Schedule
    1 For a duration of at least 2 weeks, intravenously administer one dose of a
    formulation comprising irinotecan to the patient at least once per week
    wherein each dose provides at least 100 mg/m2 of irinotecan, intravenously
    administer a formulation comprising ABDNAZ at least once per week, and
    subject the glioma to radiation therapy at least once per week.
    2 After completing step 1, do not administer any irinotecan to the patient for at
    least one week.
  • TABLE 6
    Step No. Dosing Schedule
    1 For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising irinotecan to the patient at least once per week
    wherein each dose provides at least 100 mg/m2 of irinotecan, intravenously
    administer a formulation comprising ABDNAZ at least once per week, and
    subject the glioma to radiation therapy at least twice per week.
    2 After completing step 1, do not administer any irinotecan to the patient for at
    least two weeks.
  • TABLE 7
    Step No. Dosing Schedule
    1 For a duration of at least 2 weeks, intravenously administer one dose of a
    formulation comprising irinotecan to the patient at least once per week
    wherein each dose provides at least 125 mg/m2 of irinotecan, intravenously
    administer one dose of a formulation comprising ABDNAZ at least twice
    once per week wherein each dose of the formulation comprising ABDNAZ
    provides from about 2.5 mg/m2 to about 16.5 mg/m2 of ABDNAZ, and
    subject the glioma to a dose of radiation therapy at least 2 days each week
    wherein each dose of radiation therapy provides from about 1 Gy to about 3
    Gy of radiation.
    2 After completing step 1, do not administer any irinotecan for at least one
    week.
  • TABLE 8
    Step No. Dosing Schedule
    1 For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising irinotecan to the patient once per week wherein each
    dose provides at least 125 mg/m2 of irinotecan, intravenously administer one
    dose of a formulation comprising ABDNAZ at least twice once per week
    wherein each dose of the formulation comprising ABDNAZ provides from
    about 2.5 mg/m2 to about 16.5 mg/m2 of ABDNAZ, and subject the glioma
    to a dose of radiation therapy at least 2 days each week wherein each dose of
    radiation therapy provides from about 1 Gy to about 3 Gy of radiation.
    2 After completing step 1, do not administer any irinotecan for at least one
    week.
  • TABLE 9
    Step No. Dosing Schedule
    1 For a duration of at least 3 weeks, intravenously administer one dose of a
    formulation comprising irinotecan to the patient once every three weeks
    wherein each dose provides at least 350 mg/m2 of irinotecan, intravenously
    administer one dose of a formulation comprising ABDNAZ at least twice
    once per week wherein each dose of the formulation comprising ABDNAZ
    provides from about 2.5 mg/m2 to about 16.5 mg/m2 of ABDNAZ, and
    subject the glioma to a dose of radiation therapy at least 2 days each week
    wherein each dose of radiation therapy provides from about 1 Gy to about 3
    Gy of radiation.
    2 After completing step 1, do not administer any irinotecan for at least two
    weeks.
    • Third Method—Using Bevacizumab
  • Another aspect of the invention provides a method of treating a glioma in a patient. The method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising bevacizumab, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the bevacizumab; to treat the glioma.
  • Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab has an approximate molecular weight of 149 kD and can be produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium containing the antibiotic gentamicin. Bevacizumab is marketed commercially as AVASTIN®. The formulation of bevacizumab marketed commercially as AVASTIN® is a clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion. The formulation is supplied in 100 mg and 400 mg amounts of bevacizumab in preservative-free, single-use vials. The 100 mg product is formulated in 240 mg α,α-trehalose dihydrate, 23.2 mg sodium phosphate (monobasic, monohydrate), 4.8 mg sodium phosphate (dibasic, anhydrous), 1.6 mg polysorbate 20, and Water for Injection, USP. The 400 mg product is formulated in 960 mg α,α-trehalose dihydrate, 92.8 mg sodium phosphate (monobasic, monohydrate), 19.2 mg sodium phosphate (dibasic, a 695 nhydrous), 6.4 mg polysorbate 20, and Water for Injection, USP.
    • Exemplary Features of the Method
  • The above method may be further characterized by additional features, such as the dosing schedule and amount of bevacizumab, dosing schedule of ABDNAZ, dosing amount for ABDNAZ, and features of the radiation therapy.
    • Dosing Schedule and Amount of Bevacizumab
  • The method can be further characterized according to the dosing schedule and amount of the bevacizumab. Accordingly, in certain embodiments, the formulation comprising bevacizumab is administered once every 2 weeks for a duration of at least 4 weeks. In certain embodiments, the formulation comprising bevacizumab is administered once every 3 weeks for a duration of at least 6 weeks.
  • In certain embodiments, the patient receives the formulation comprising bevacizumab by (i) intravenous infusion once every 2 weeks at a dose of at least about 5 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, (ii) intravenous infusion once every 2 weeks at a dose of at least about 10 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, or (iii) intravenous infusion once every 3 weeks at a dose of at least about 15 mg/kg of bevacizumab for a duration of at least 6, 12, 15, or 18 weeks. In certain embodiments, the patient receives the formulation comprising bevacizumab by intravenous infusion once every 2 weeks at a dose of 5-10 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks.
  • In certain other embodiments, the patient receives the formulation comprising bevacizumab by (i) intravenous infusion once every 2 weeks at a dose of about 5 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, (ii) intravenous infusion once every 2 weeks at a dose of about 10 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks, or (iii) intravenous infusion once every 3 weeks at a dose of about 15 mg/kg of bevacizumab for a duration of at least 6, 12, 15, or 18 weeks. In certain embodiments, the patient receives the formulation comprising bevacizumab by intravenous infusion once every 2 weeks at a dose of 5-20 mg/kg of bevacizumab for a duration of at least 4, 6, 8, 10, or 12 weeks.
    • Dosing Schedule for ABDNAZ
  • A formulation comprising ABDNAZ may be administered multiple times, such as multiple times over a defined period of time. Further, coordination of the dosing schedule of the bevacizumab and radiation therapy with that of the formulation comprising ABDNAZ is contemplated to provide therapeutic benefits, such as superior efficacy.
  • In certain embodiments, two doses of a therapeutically effective amount of a formulation comprising ABDNAZ are administered within about 7 days of administration of the first dose of bevacizumab. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of bevacizumab, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of bevacizumab, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ. In certain embodiments, the patient receives ABDNAZ within about 6 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 24 hours prior to subjecting the glioma to radiation therapy. In certain embodiments, the patient receives ABDNAZ within about 48 hours prior to subjecting the glioma to radiation therapy.
  • In certain embodiments, the formulation comprising ABDNAZ is administered so that the ABDNAZ exerts physiological activity during an overlapping time period with one or both of the radiation therapy and bevacizumab.
    • Dose of ABDNAZ Administered
  • The dose ABDNAZ described herein for use in combination with bevacizumab and radiation therapy has been selected in view of the dosing amount and dosing schedule of the bevacizumab and radiation therapy. Dosing amounts of ABDNAZ are provided according to the number of milligrams of ABDNAZ to be administered to the patient based on the surface area of the patient as measured in m2.
  • In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2 mg/m2 to about 20 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 2.5 mg/m2 to about 5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 5 mg/m2 to about 10 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount ranging from about 10 mg/m2 to about 16.5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 2.5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 5 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 10 mg/m2. In certain embodiments, each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of about 16.5 mg/m2.
    • Radiation Therapy Features
  • In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 3 days within a 7 day period following administration of the first dose of bevacizumab. In certain embodiments, the glioma is subjected to radiation therapy once per day for at least 5 days within a 7 day period following administration of the first dose of bevacizumab. In certain embodiments, for a duration of at least 2 weeks following administration of the first dose of bevacizumab, the glioma is subjected to radiation therapy once per day for at least 5 days of each week. In certain embodiments, for a duration of at least 4 weeks following administration of the first dose of bevacizumab, the glioma is subjected to radiation therapy once per day for at least 5 days of each week.
  • In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is from about 1 Gy to about 3 Gy. In certain embodiments, when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is about 2 Gy.
  • In certain embodiments, the glioma is exposed to from about 50 Gy to about 70 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of bevacizumab. In certain embodiments, the glioma is exposed to about 60 Gy of radiation by the radiation therapy over a period of 6 weeks following administration of the first dose of bevacizumab.
  • In certain embodiments, the radiation therapy is (i) conventional fractionated external beam radiation or (ii) intensity-modulated radiation therapy. In certain embodiments, the radiation therapy is (i) conventional fractionated external beam radiation.
  • Various types of radiation therapy are used by those skilled in the art and have been described in the literature. Exemplary types of radiation therapy include, for example, radiation therapy comprising gamma rays, X-rays, electron beams, neutron beams, particulate radiation, proton beams, or the like. The source of the radiation is desirably external to the patient, which involves directing a beam of high-energy radiation to the glioma using a machine external to the patient. Desirably the target site (i.e., site of the glioma) is exposed to the radiation therapy for a short duration of time, such as less than about 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute for each dose of radiation therapy.
    • Combinations of Embodiments and Illustration of Exemplary More Specific Methods
  • All combinations of aspects and embodiments described above are contemplated. For example, a therapeutic method is contemplated for treating a glioblastoma by administering to a patient in need thereof for a duration of at least 3 weeks, orally administer one dose of a formulation comprising bevacizumab to the patient daily, intravenously administer a formulation comprising ABDNAZ at least once per week, and subject the glioma to radiation therapy at least 3 days each week. Exemplary more specific illustrations of the contemplated dosing methods for treating a glioma (e.g., a glioblastoma) using bevacizumab are provided below in Table 10 below describing multiple more specific dosing schedules.
  • TABLE 10
    Dosing
    Schedule Description of Dosing Schedule
    A For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every two weeks
    wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least once per week, and
    subject the glioma to radiation therapy at least once per week.
    B For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every two weeks
    wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least once per week, and
    subject the glioma to radiation therapy at least twice per week.
    C For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every two weeks
    wherein each dose provides at least 10 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least once per week, and
    subject the glioma to radiation therapy at least twice per week.
    D For a duration of at least 6 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every three weeks
    wherein each dose provides at least 15 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least once per week, and
    subject the glioma to radiation therapy at least twice per week.
    E For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every two weeks
    wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least twice per week, and
    subject the glioma to radiation therapy at least twice per week.
    F For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every two weeks
    wherein each dose provides at least 10 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least twice per week, and
    subject the glioma to radiation therapy at least twice per week.
    G For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every two weeks
    wherein each dose provides at least 5 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least twice per week
    wherein each dose of the formulation comprising ABDNAZ provides from
    about 2.5 mg/m2 to about 16.5 mg/m2 of ABDNAZ, and subject the glioma
    to radiation therapy at least twice per week wherein each dose of radiation
    therapy provides from about 1 Gy to about 3 Gy of radiation.
    H For a duration of at least 4 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every two weeks
    wherein each dose provides at least 10 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least twice per week
    wherein each dose of the formulation comprising ABDNAZ provides from
    about 2.5 mg/m2 to about 16.5 mg/m2 of ABDNAZ, and subject the glioma
    to radiation therapy at least twice per week wherein each dose of radiation
    therapy provides from about 1 Gy to about 3 Gy of radiation.
    I For a duration of at least 6 weeks, intravenously administer one dose of a
    formulation comprising bevacizumab to the patient once every three weeks
    wherein each dose provides at least 15 mg/kg of bevacizumab, intravenously
    administer a formulation comprising ABDNAZ at least twice per week
    wherein each dose of the formulation comprising ABDNAZ provides from
    about 2.5 mg/m2 to about 16.5 mg/m2 of ABDNAZ, and subject the glioma
    to radiation therapy at least twice per week wherein each dose of radiation
    therapy provides from about 1 Gy to about 3 Gy of radiation.
    • Further Characterization of the First, Second, and Third Methods
  • The methods may be further characterized according to, for example, the type of glioma, patients for treatment, effects of the treatment, formulation of ABDNAZ, and form of ABDNAZ.
    • Type of Glioma
  • The methods may be further characterized according to the nature of the glioma. In certain embodiments, the glioma is an astrocytoma. In certain embodiments, the glioma is a malignant astrocytoma. In certain embodiments, the glioma is a glioblastoma. In certain embodiments, the glioma is a primary glioblastoma. In certain embodiments, the glioma is a secondary glioblastoma. In certain embodiments, the glioma is a gliosarcoma. In certain embodiments, the glioma is an anaplastic glioma with 1p/19q chromosomes intact. In certain embodiments, the glioma is an anaplastic oligodendroglioma or anaplastic oligoastrocytoma.
    • Patients for Treatment
  • The therapeutic method may be further characterized according to the patient to be treated. In certain embodiments, the patient is an adult human. In certain other embodiments, the patient is a pediatric human. In certain embodiments, the patient has previously undergone surgery to remove at least some glioma tissue. In certain embodiments, the patient has previously undergone surgery, to remove at least some glioma tissue, within six weeks prior to receiving the first dose of temozolomide under the methods described herein using ABDNAZ as part of a combination therapy treatment.
    • Characterization of Treatment Effects
  • The therapeutic method may be further characterized according to the effect of the treatment, such as (i) a reduction in the size of at least one glioma tumors in the patient, and/or (ii) reduction in the number of glioma tumor in the patient.
  • Accordingly, in certain embodiments, the therapeutic method is characterized by at least a 20% reduction in the size of at least one glioma tumor in the patient. In certain other embodiments, there is at least a 35% reduction in the size of at least one glioma tumor in the patient. In certain other embodiments, there is at least a 50% reduction in the size of at least one glioma tumor in the patient.
  • In certain embodiments, there is at least a 20% reduction in the number of glioma tumors in the patient. In certain other embodiments, there is at least a 35% reduction in the number of glioma tumors in the patient. In yet other embodiments, there is at least a 50% reduction in the number of glioma tumors in the patient.
    • Exemplary Formulations Comprising ABDNAZ
  • The method may be further characterized according to the formulation comprising ABDNAZ that is administered to the patient. In certain embodiments, the formulation comprises ABDNAZ, dimethylacetamide, water, and a polyethylene glycol. In certain embodiments, the polyethylene glycol has a number-average molecular weight of about 400 g/mol.
    • Form of ABDNAZ
  • In certain embodiments, the patient may be administered a pharmaceutically acceptable salt of ABDNAZ.
    • Methods for Increasing the Amount of Temozolomide, Irinotecan, or Bevacizumab in a Glioma
  • Another aspect of the invention provides a method for increasing the amount of temozolomide, irinotecan, or bevacizumab in a glioma. The method generally involves administering to a patient having a glioma (i) a formulation comprising temozolomide, irinotecan, or bevacizumab and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the temozolomide, irinotecan, or bevacizumab is present in the patient, in order to increase the amount of the temozolomide, irinotecan, or bevacizumab in the glioma. The method may be characterized according to the percent increase in the amount of temozolomide, irinotecan, or bevacizumab in the glioma relative to the amount of temozolomide, irinotecan, or bevacizumab in the glioma following an identical administration procedure but absent administering said effective amount of a formulation comprising ABDNAZ.
  • Accordingly, one aspect of the invention provides a method of increasing the amount of temozolomide in a glioma, where the method comprises administering to a patient having a glioma (i) a formulation comprising temozolomide and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the temozolomide is present in the patient, in order to increase the amount of the temozolomide in the glioma.
  • Another aspect of the invention provides a method of increasing the amount of irinotecan in a glioma, where the method comprises administering to a patient having a glioma (i) a formulation comprising irinotecan and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the irinotecan is present in the patient, in order to increase the amount of the irinotecan in the glioma.
  • Another aspect of the invention provides a method of increasing the amount of bevacizumab in a glioma, where the method comprises administering to a patient having a glioma (i) a formulation comprising bevacizumab and (ii) an effective amount of a formulation comprising ABDNAZ so that the ABDNAZ exerts physiological activity during a time period in which the bevacizumab is present in the patient, in order to increase the amount of the bevacizumab in the glioma.
  • Each of the foregoing methods may be further characterized according to features described above in connection with the First, Second, and Third Methods. Additionally, the foregoing methods may be further characterized according to the percent increase (e.g., at least a 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or 300% increase) in the amount of temozolomide, irinotecan, or bevacizumab in the glioma relative to the amount of temozolomide, irinotecan, or bevacizumab in the glioma following an identical administration procedure but absent administering said effective amount of a formulation comprising ABDNAZ.
  • In certain embodiments, the formulation comprising ABDNAZ is administered within about 4, 6, 8, 10, 12, 14, 16, 18, 20 or 24 hours of administration of a formulation comprising one of temozolomide, irinotecan, or bevacizumab.
    • Additional Method—Using Temozolomide
  • Another aspect of the invention provides a method of treating a glioma in a patient. The method comprises the steps of: (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising ABDNAZ, and (b) thereafter administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide; to treat the glioma. The method may be further characterized by additional features, such as the dosing schedule and amount of temozolomide, dosing schedule of ABDNAZ, dosing amount for ABDNAZ, and/or any rest period/maintenance period, as described above in connection with the First Method.
    • IV. Pharmaceutical Compositions
  • The invention provides pharmaceutical compositions comprising an active therapeutic agent and one or more pharmaceutically acceptable carriers (additives) and/or diluents. In certain embodiments, the active therapeutic agent is ABDNAZ, such that the invention provides a pharmaceutical composition comprising ABDNAZ formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. The a pharmaceutical composition may comprise ABDNAZ in a therapeutically effective amount. As described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions); and (2) parenteral administration by, for example, subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation.
  • The phrase “therapeutically-effective amount” as used herein means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
  • The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
  • Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • The preparations of the present invention may be given, for example, orally or parenterally. The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Preferably, the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg. When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may be less than when the agent is used alone.
  • If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
  • The description above describes multiple aspects and embodiments of the invention. The patent application specifically contemplates all combinations and permutations of the aspects and embodiments.
    • V. Kits for Use in Medical Applications
  • Another aspect of the invention provides a kit for treating a glioma. The kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma according to procedures described herein, such as (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma. In an alternative embodiment, the kit comprises: (i) a formulation comprising ABDNAZ, and (ii) instructions for treating a glioma that comprise (a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and (b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma.
    • VI. Definitions
  • To facilitate an understanding of the present invention, a number of terms and phrases are defined below.
  • The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.
  • As used herein, the term “patient” refers to organisms to be treated by the methods of the present invention. Such organisms are preferably mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably humans.
  • As used herein, the term “effective amount” refers to the amount of a compound (e.g., a compound of the present invention) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
  • As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
  • As used herein, the terms “alleviate” and “alleviating” refer to reducing the severity of the condition, such as reducing the severity by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.
  • As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
  • As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. [1975]).
  • As used herein, the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof. As is known to those of skill in the art, “salts” of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Examples of bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW4+, wherein W is C1-4 alkyl, and the like.
  • Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as Na+, NH4+, and NW4+ (wherein W is a C1-4 alkyl group), and the like.
  • For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
  • Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
  • As a general matter, compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.
    • EXAMPLES
  • The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
    • Example 1—Treatment of Human Patients Suffering from a Glioblastoma or Malignant Glioma
  • Adult human patients having a gliobastoma or malignant glioma are to be treated using a combination of ABDNAZ, temozolomide, and radiation therapy (RT) according to the treatment protocol described below.
    • Treatment Protocol Upfront Therapy
  • Patients are to receive oral temozolomide 75 mg/m2 daily for 6 weeks and undergo conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) 5 days a week for 6 weeks. Patients are also to receive ABDNAZ by intravenous administration twice weekly for 6 weeks administered at one of four dose levels (2.0 mg/m2, 8 mg/m2, 17 mg/m2, or 29 mg/m2) beginning concurrently with temozolomide and radiotherapy. Cohorts of 3-6 patients will receive escalating doses of ABDNAZ until the maximum feasible dose (MFD) or maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 subjects experience dose-limiting toxicity.
    • Maintenance Therapy
  • Beginning 28 days after completion of radiotherapy, patients are to receive oral temozolomide [150 mg/m2 orally daily for 5 days during cycle 1 (28 days) and 200 mg/m2 orally daily for 5 days every 28 days for cycles 2-6] and once weekly ABDNAZ at 2 mg/m2 on days 1-28. Treatment will repeat every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
    • Patient Evaluation Procedure
  • Patients are to be evaluated by a radiation oncologist and medical oncologist prior to the start of any treatment. Efficacy of the therapy may be evaluated according to procedure described below.
  • Pre-Treatment Evaluation (within 14±7 Days Prior to First Dose of Study Drug)
  • Patients may be evaluated using the following criteria prior to treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
      • GAD-enhanced DCE-MRI
      • Contrast-enhanced MM and/or CT
      • Complete history and general physical exam
      • Detailed neurological examination
      • Safety labs: CBC with differential, comprehensive chemistry panel, liver function tests
      • Karnofsky performance status
      • Documentation of primary tumor histology
      • Documentation of steroid and anticonvulsant doses and any other concomitant medications. The newer antiepilieptic drugs (levetiracetam, pregabalin, lamotrigine, lacosamide, topiramate) are generally preferred over carbamazepine, phenytoin, phenobarbital, or valproic acid, which stimulate the hepatic cytochrome P450 (CYP) system.
      • FACT-BR, Barthel Index of ADLs, and neurocognitive function (HVLT-R, COWA, and Trail Making A and B) will be evaluated
    Evaluation During Radiation Therapy and ABDNAZ Therapy
  • Patients may be evaluated using the following criteria during treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
      • Clinical visit once per week to include neurological examination, history and physical examination and clinical laboratory testing
      • GAD-enhanced DCE-MRI on days 9±1 day and 41±1 day
      • Collection of concomitant medications at each clinic visit
      • Collection of adverse events (AEs) at each clinic visit
      • Skin within the treatment portal shall be examined once per week during radiation treatment
        Evaluation after Completion of Radiation Therapy and ABDNAZ Therapy
  • Patients may be evaluated using the following criteria after treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
      • Patients are to be evaluated 2 weeks after completion of radiation therapy and ABDNAZ treatment with neurological exam, history and symptom-directed physical examination, and clinical laboratory testing
      • During the maintenance phase, patients are to be evaluated on Day 1±2 days of each 4-week cycle. Each evaluation will consist of neurological examination, history and symptom-directed physical examination, ECOG performance status, FACT-BR, Barthel Index of ADLs, and neurocognitive function
      • Safety labs every 4 weeks on Day 1±2 days for Cycles 2+(CBC with differential, comprehensive chemistry panel, liver function tests). Radiologic evaluation will occur every 8 weeks as per Standard of Care
      • Patients are to be evaluated with contrast-enhanced MRI w/GAD prior to starting Cycle 1 and at least every 2 months (after every 2 cycles) of ABDNAZ/temozolomide as well as neurocognitive testing at 4 months±7 days (1 month=4 weeks or 28 days) after completion of radiation therapy/ABDNAZ
      • Collection of concomitant medications at each clinic visit
      • Collection of adverse events (AEs) at each clinic visit
    General Features
  • During Upfront Therapy and Maintenance Therapy described above, temozolomide is to be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days (to allow for treatments interruptions, for example, over holidays). The drug will be administered at night just before bedtime. The dose will be determined using actual body surface area (BSA) as defined by the method of DuBois and DuBois. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose is to be rounded to the nearest 5 mg. Patients are to be instructed to swallow the capsules whole, in rapid succession, without chewing them. If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed before the next scheduled dose. The capsules should be taken on an empty stomach, therefore a minimum of 2 hours after eating and with no food consumption for at least 1 hour after temozolomide administration. Water is allowed during the fast period. Administration of the higher dosing regimen during the maintenance phase of the protocol should also be at night. However, prophylaxis with a 5-HT3 antagonist is recommended prior to administration of the first few temozolomide doses and may be administered orally 30 to 60 minutes before temozolomide treatment.
  • For radiation therapy, 2 Gy of radiation is to be given daily 5 days per week for a total of 60 Gy over 6 weeks. All fields shall be treated during each treatment session. Doses are specified such that at least 95% of the planning treatment volume (PTV) shall receive 100% of the prescribed dose; Dose Volume Histograms (DVHs) may be necessary to make this selection. Radiation therapy will be delivered using standard dose and fractionation as described below:
      • Simulation, Immobilization: Patients are to be treated in the supine position. Adequate immobilization and reproducibility of position will be ensured using thermoplastic mask.
      • Target: The target volume for both the initial volume and the conedown volume shall be based on CT/MRI. This initial target volume shall include the contrast-enhancing lesion and surrounding edema (if it exists) demonstrated on CT/MRI plus a margin. If no surrounding edema is present, the initial target volume should include the contrast enhancing lesion plus a margin. The initial target volume will be treated to 46 Gy in 23 fractions. After 46 Gy, the tumor volume for the conedown treatment should include the contrast enhancing lesion (without edema) on the CT/MRI scan plus a margin. Isodose distributions for the initial target volume and the conedown target volume are required on all patients, including those treated with parallel opposed fields. The inhomogeneity within the target volume shall be kept to 10%. The minimum dose to the target volume should be kept within 10% of the dose at the center of the volume.
      • Dose Limitations: The lens and cervical spine should be shielded from the direct beam at all times. When possible to do without shielding gross tumor, attempts should be made to limit the dose to the optic chiasm to 54 Gy, the retina of at least one eye (but preferably both) to 50 Gy, and the brainstem to 60 Gy. When the optic chiasm must be included in the full dose, then there may be a finite unknown risk of developing blindness.
      • Dose Specification: Radiotherapy is to be delivered with a daily fraction size of 2.0 Gy per fraction given 5 days a week for a total of 60 Gy over 6 weeks.
      • Technique: Treatment will be delivered with megavoltage machines with a minimum energy of 6 MV photons. All fields will be treated during each treatment session. Treatment plans may include opposed lateral fields, a wedge pair of fields, rotation, or multiple field techniques. Intensity-modulated inverse-planned approaches are permitted. Any of the methods of IMRT (including tomotherapy) may be used, subject to protocol localization and dosimetry constraints. CT-based treatment planning is desirable to assure accuracy in the selection of field arrangements. MRI-fusion for accurate target delineation is recommended.
    Example 2—Treatment of Human Patients Suffering from a Glioblastoma or Malignant Glioma
  • Adult human patients having a gliobastoma or malignant glioma are to be treated using a combination of ABDNAZ (by intravenous administration at a dose ranging from 0.5 mg to 4.0 mg), temozolomide, and radiation therapy (RT) according to the treatment protocol described below.
    • Treatment Protocol Upfront Therapy
  • Patients are to receive oral temozolomide 75 mg/m2 daily for 6 weeks and undergo conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) 5 days a week for 6 weeks. Patients are also to receive ABDNAZ by intravenous administration once weekly for 6 weeks administered at one of four dose levels (0.5 mg, 1.0 mg, 2.0 mg, or 4.0 mg) beginning concurrently with temozolomide and radiotherapy. Cohorts of 3-6 patients will receive escalating doses of ABDNAZ until the maximum feasible dose (MFD) or maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 subjects experience dose-limiting toxicity. Administration of temozolomide is no sooner than 4 hours after administration of ABDNAZ. ABDNAZ is preferably administered within three hours prior to administration of radiation therapy.
    • Maintenance Therapy
  • Beginning 4-6 weeks after completion of radiotherapy, patients are to receive oral temozolomide [150 mg/m2 orally daily for on days 1-5 during cycle 1 (28 days) and 200 mg/m2 orally daily on days 1-5 during cycles 2-6 (where each cycle is 28 days)] and once weekly ABDNAZ by intravenous administration at a dose ranging from 0.5 mg to 4.0 mg for six months. Administration of temozolomide is no sooner than 4 hours after administration of ABDNAZ.
    • Patient Evaluation Procedure
  • Patients are to be evaluated by a neuro-oncologist, radiation oncologist, or medical oncologist prior to the start of any treatment. Efficacy of the therapy may be evaluated according to procedure described below.
  • Pre-Treatment Evaluation (within 14±7 Days Prior to First Dose of Study Drug)
  • Patients may be evaluated using the following criteria prior to treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
      • Contrast-enhanced MRI
      • Complete history and general physical exam
      • Detailed neurological examination
      • Safety labs: CBC with differential, comprehensive chemistry panel with liver function tests
      • Karnofsky performance status
      • Documentation of primary tumor histology
      • Documentation of steroid and anticonvulsant doses and any other concomitant medications. The newer antiepilieptic drugs (levetiracetam, pregabalin, lamotrigine, lacosamide, topiramate) are generally preferred over carbamazepine, phenytoin, phenobarbital, or valproic acid, which stimulate the hepatic cytochrome P450 (CYP) system.
    Evaluation During Radiation Therapy and ABDNAZ Therapy
  • Patients may be evaluated using the following criteria during treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
      • Clinical visit once per week to include neurological examination, history and physical examination and clinical laboratory testing
      • Documentation of concomitant medications at each clinic visit
      • Collection of adverse events (AEs) at each clinic visit
      • Skin within the treatment portal shall be examined once per week during radiation treatment
      • Serum magnesium test during week 4
    Evaluation After Completion of Radiation Therapy and ABDNAZ Therapy
  • Patients may be evaluated using the following criteria after treatment with the therapy to assess nature and extent of the gliobastoma or malignant glioma:
      • Patients are to be evaluated 3-5 weeks after completion of radiation therapy and ABDNAZ treatment with neurological exam, history and symptom-directed physical examination, adverse events, concomitant medications, and clinical laboratory testing
      • During the maintenance phase, patients are to be evaluated on Day 1±2 days of each 4-week cycle. Each evaluation will consist of neurological examination, history and symptom-directed physical examination, and KPS/ECOG performance status
      • Safety labs every 4 weeks on Day 1±2 days for Cycles 2+(CBC with differential, comprehensive chemistry panel, liver function tests). Radiologic evaluation will occur every 8 weeks as per Standard of Care
      • Patients are to be evaluated with contrast-enhanced MM w/GAD prior to starting Cycle 1 and at least every 2 months (after every 2 cycles) of ABDNAZ/temozolomide as well as neurocognitive testing at 4 months±7 days (1 month=4 weeks or 28 days) after completion of radiation therapy/ABDNAZ
      • Collection of concomitant medications at each clinic visit
      • Collection of adverse events (AEs) at each clinic visit
    General Features
  • During Upfront Therapy and Maintenance Therapy described above, temozolomide is to be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days (to allow for treatments interruptions, for example, over holidays). The drug will be administered at night just before bedtime. The dose will be determined using actual body surface area (BSA) as defined by the method of DuBois and DuBois. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose is to be rounded to the nearest 5 mg. Patients are to be instructed to swallow the capsules whole, in rapid succession, without chewing them. If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed before the next scheduled dose. The capsules should be taken on an empty stomach, therefore a minimum of 2 hours after eating and with no food consumption for at least 1 hour after temozolomide administration. Water is allowed during the fast period. Administration of the higher dosing regimen during the maintenance phase of the protocol should also be at night. However, prophylaxis with a 5-HT3 antagonist is recommended prior to administration of the first few temozolomide doses and may be administered orally 30 to 60 minutes before temozolomide treatment.
  • For radiation therapy, 2 Gy of radiation is to be given daily 5 days per week for a total of 60 Gy over 6 weeks. All fields shall be treated during each treatment session. Doses are specified such that at least 95% of the planning treatment volume (PTV) shall receive 100% of the prescribed dose; Dose Volume Histograms (DVHs) may be necessary to make this selection. Radiation therapy will be delivered using standard dose and fractionation as described below:
      • Simulation, Immobilization: Patients are to be treated in the supine position. Adequate immobilization and reproducibility of position will be ensured using thermoplastic mask.
      • Target: The target volume for both the initial volume and the conedown volume shall be based on CT/MRI. This initial target volume shall include the contrast-enhancing lesion and surrounding edema (if it exists) demonstrated on CT/MRI plus a margin. If no surrounding edema is present, the initial target volume should include the contrast enhancing lesion plus a margin. The initial target volume will be treated to 46 Gy in 23 fractions. After 46 Gy, the tumor volume for the conedown treatment should include the contrast enhancing lesion (without edema) on the CT/MRI scan plus a margin. Isodose distributions for the initial target volume and the conedown target volume are required on all patients, including those treated with parallel opposed fields. The inhomogeneity within the target volume shall be kept to 10%. The minimum dose to the target volume should be kept within 10% of the dose at the center of the volume.
      • Dose Limitations: The lens and cervical spine should be shielded from the direct beam at all times. When possible to do without shielding gross tumor, attempts should be made to limit the dose to the optic chiasm to 54 Gy, the retina of at least one eye (but preferably both) to 50 Gy, and the brainstem to 60 Gy. When the optic chiasm must be included in the full dose, then there may be a finite unknown risk of developing blindness.
      • Dose Specification: Radiotherapy is to be delivered with a daily fraction size of 2.0 Gy per fraction given 5 days a week for a total of 60 Gy over 6 weeks.
      • Technique: Treatment will be delivered with megavoltage machines with a minimum energy of 6 MV photons. All fields will be treated during each treatment session. Treatment plans may include opposed lateral fields, a wedge pair of fields, rotation, or multiple field techniques. Intensity-modulated inverse-planned approaches are permitted. Any of the methods of IMRT (including tomotherapy) may be used, subject to protocol localization and dosimetry constraints. CT-based treatment planning is desirable to assure accuracy in the selection of field arrangements. MRI-fusion for accurate target delineation is recommended.
    Example 3—Administration of ABDNAZ and Temozolomide to a GBM14 TMZ-S Patient-Derived Cell Line and a GBM14 TMZ-R Patient-Derived Cell Line
  • Temozolomide-sensitive human GBM14 (GBM14 TMZ-S) patient derived cell line cells were treated with one of the following (i) ABDNAZ, (ii) temozolomide, or (iii) ABDNAZ and temozolomide. In a separate experiment, temozolomide-resistant human GBM14 (GBM14 TMZ-R) patient derived cell line cells were treated with one of the following (i) ABDNAZ, (ii) temozolomide, or (iii) ABDNAZ and temozolomide. Experimental procedures and results are provided below.
    • Part I—Procedures
  • In a first experiment, temozolomide-sensitive human GBM14 (GBM14 TMZ-S) patient derived cell line cells were treated with one of the following (i) ABDNAZ at a concentration of 2 μM, (ii) temozolomide at a concentration of 100 μM, or (iii) ABDNAZ (at a concentration of 2 μM) and temozolomide (at a concentration of 100 μM). WST-1 assay was used to assess the effect of treatment on cell viability over the time of three days. The presence of live cells is detected by absorbance at 440 nm in the assay. Data are presented as the mean±3 standard deviations from three separate performances of the experiment.
  • In a second experiment, temozolomide-resistant human GBM14 (GBM14 TMZ-R) patient derived cell line cells were treated with one of the following (i) ABDNAZ at a concentration of 2 μM, (ii) temozolomide at a concentration of 100 μM, or (iii) ABDNAZ (at a concentration of 2 μM) and temozolomide (at a concentration of 100 μM). The presence of live cells is detected by absorbance at 440 nm in the assay. WST-1 assay was used to assess the effect of treatment on cell viability over the time of three days. Data are presented as the mean±3 standard deviations from three separate performances of the experiment.
    • Part II—Results
  • Results are presented in FIG. 1 showing response from the GBM14 TMZ-S patient derived cell line and FIG. 2 showing response from the GBM14 TMZ-R patient derived cell line. As indicated by data in FIGS. 1 and 2, administration of ABDNAZ and temozolomide together produced a greater amount of cell death as measured by lack of absorbance at 440 nm.
    • Example 4—Administration of ABDNAZ and Temozolomide to NSCG Cells In Vitro
  • Cells from temozolomide-resistant murine EGFRvIII/Arfko neural stem cell-derived glioma (NSCG) cell line were treated with one of the following: (i) ABDNAZ (RRx-001), (ii) temozolomide (TMZ), or (iii) ABDNAZ and temozolomide. Experimental procedures and results are provided below.
    • Part I—Procedures
  • Cells from temozolomide-resistant murine EGFRvIII/Arfko neural stem cell-derived glioma (NSCG) cell line were treated with one of the following (i) ABDNAZ at a concentration of 2 μM, (ii) temozolomide at a concentration of 100 μM, or (iii) ABDNAZ (at a concentration of 2 μM) and temozolomide (at a concentration of 100 μM). WST-1 assay was used to assess the effect of treatment on cell viability over the time of five days. The presence of live cells is detected by absorbance at 440 nm in the assay. Data are presented as the mean±3 standard deviations from three separate performances of the assay.
    • Part II—Results
  • Results are presented in FIG. 3, where the data indicate that administration of ABDNAZ and temozolomide together produced a greater amount of cell death as measured by lack of absorbance at 440 nm. Data are presented as the mean±3 standard deviations from three separate performances of the assay.
    • Example 5—Administration of ABDNAZ and Temozolomide to Mice Implanted with NSCG Tumors
  • Mice implanted with temozolomide-resistant EGFRvIII/Arfko GBM (NSCG) cells were treated with (i) ABDNAZ (RRx-001, 10 mg/kg, intraperitoneal injection), (ii) temozolomide (TMZ)(40 mg/kg, oral gavage), or (iii) ABDNAZ (10 mg/kg, intraperitoneal injection) and temozolomide (40 mg/kg, oral gavage). Experimental procedures and results are provided below.
    • Part I—Procedures
  • NSCG tumors were intracranially injected into FVBN mice. Mice to be treated were treated with one of the following (i) ABDNAZ (10 mg/kg, intraperitoneal injection), (ii) temozolomide (40 mg/kg, oral gavage), or (iii) ABDNAZ (10 mg/kg, intraperitoneal injection) and temozolomide (40 mg/kg, oral gavage). In a first experiment, treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started five days after intracranial injection of NSCG cells. The control population of mice contained ten mice, the group receiving only ABDNAZ had twelve mice, the group receiving only temozolomide had twelve mice, and the group receiving both ABDNAZ and temozolomide had sixteen mice. Mouse survival was monitored over time.
  • In a second experiment, treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started ten days after intracranial injection of NSCG cells. The control population of mice contained three mice, the group receiving only ABDNAZ had five mice, the group receiving only temozolomide had four mice, and the group receiving both ABDNAZ and temozolomide had six mice. Mouse survival was monitored over time.
    • Part II—Results
  • Results are presented in FIGS. 4 and 5 and Tables 1 and 2 below. FIG. 4 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started five days after intracranial injection of NSCG cells. The abbreviation “CTL” in FIG. 4 refers to control subjects. Table 1 shows median survival time (in days) observed in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started five days after intracranial injection of NSCG cells.
  • FIG. 5 is a graph showing percent survival of subjects over time, in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started ten days after intracranial injection of NSCG cells. The abbreviation “CTL” in FIG. 5 refers to control subjects. Table 2 shows median survival time (in days) observed in the experiment in which treatment (i.e., administration of ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide) was started ten days after intracranial injection of NSCG cells.
  • TABLE 1
    Subjects
    Population Population Population
    Receiving Receiving Only Receiving Both
    Control Only TMZ ABDNAZ ABDNAZ & TMZ
    Median 22.2 22.3 25.3 30.4
    Survival (ns) (p = 0.072) (p = 0.003)
    Time (days)
  • TABLE 2
    Subjects
    Population Population Population
    Receiving Receiving Only Receiving Both
    Control Only TMZ ABDNAZ ABDNAZ & TMZ
    Median 22.1 22.3 22.5 27.2
    Survival (ns) (ns) (p = 0.174)
    Time (days)
    • Example 6—Administration of ABDNAZ and Temozolomide to Mice Implanted with NSCG Tumors
  • Mice implanted with TMZ-resistant EGFRvIII/Arfko GBM tumors (NSCG tumors) were treated with ABDNAZ (RRx-001), temozolomide (TMZ), or both ABDNAZ and temozolomide. Experimental procedures and results are provided below.
    • Part I—Procedures
  • NSCG tumors were orthotopically implanted in FVBN mice. Then, the mice were treated with one of the following (i) ABDNAZ (10 mg/kg, intraperitoneal injection), (ii) temozolomide (40 mg/kg, oral gavage), or (iii) ABDNAZ (10 mg/kg, intraperitoneal injection) and temozolomide (40 mg/kg, oral gavage). Percent apoptosis of CC3+ cells was evaluated.
    • Part II—Results
  • The amount of CC3+ cell apoptosis detected in the assay is shown in FIG. 6. As indicated by data in FIG. 6, administration of ABDNAZ and temozolomide together produced the highest percentage of CC3+ cell apoptosis. The abbreviation “CTL” refers to control mice; the symbol *** refers to p<0.001.
    • Example 7—Administration of ABDNAZ and Temozolomide to Mice Implanted with Brain Tumors
  • Mice implanted with brain tumors were treated with ABDNAZ, temozolomide (TMZ), or both ABDNAZ and temozolomide. Experimental procedures and results are provided below.
    • Part I—Procedures
  • Brain tumors were orthotopically implanted in the brain of mice. Then, the mice were treated with one of the following (i) ABDNAZ, (ii) temozolomide, or (iii) ABDNAZ followed by administration of temozolomide 4 hours later. ABDNAZ (10 mg/kg) was administered via tail vein 4 hours before any temozolomide (20 mg/kg) via tail vein once weekly for 4 weeks. Twenty-four hours after temozolomide administration, tumor-bearing mice were euthanized and brain tumor tissue was collected and dissected. Temozolomide levels in tumor tissues were measured.
    • Part II—Results
  • The concentration of temozolomide (TMZ) detected in brain tumor tissue of the mice is shown in FIG. 7. As indicated by data in FIG. 7, administration of ABDNAZ prior to administration of temozolomide resulted in a greater concentration of temozolomide in the brain tumor tissue.
    • Example 8—Administration of ABDNAZ and Irinotecan to Mice Implanted with Human Glioblastoma GBM43 Brain Tumors
  • Mice implanted with human glioblastoma GBM43 brain tumors were treated with ABDNAZ, irinotecan, or both ABDNAZ and irinotecan. Experimental procedures and results are provided below.
    • Part I—Procedures
  • Human glioblastoma GBM43 tumors were orthotopically implanted in the brain of immunocompromised mice. Then, the mice were treated with one of the following (i) ABDNAZ, (ii) irinotecan, or (iii) ABDNAZ followed by administration of irinotecan 4 hours later. Twenty-four hours after irinotecan administration, tumor-bearing mice were euthanized and brain tumor tissue was collected and dissected. Irinotecan levels in tumor tissues were measured.
    • Part II—Results
  • The concentration of irinotecan detected in brain tumor tissue of the mice is shown in FIG. 8. As indicated by data in FIG. 8, administration of ABDNAZ prior to administration of irinotecan resulted in a greater concentration of irinotecan in the brain tumor tissue.
    • INCORPORATION BY REFERENCE
  • The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.
    • EQUIVALENTS
  • The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

Claims (33)

1. A method of treating a glioma in a patient, comprising the steps of:
(a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising temozolomide, and within about 2 days thereafter subjecting the glioma to radiation therapy; and
(b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the temozolomide; to treat the glioma;
wherein each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 20 mg.
2. The method of claim 1, wherein the formulation comprising temozolomide is administered daily for at least 2 weeks.
3.-5. (canceled)
6. The method of claim 1, wherein the patient receives temozolomide by oral administration at a daily dose of at least 50 mg/m2.
7.-8. (canceled)
9. The method of claim 1, wherein for a duration of at least 2 weeks following administration of the first dose of temozolomide, the patient receives at least one dose each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
10.-11. (canceled)
12. The method of claim 1, wherein two doses of a therapeutically effective amount of a formulation comprising ABDNAZ are administered within about 7 days of administration of the first dose of temozolomide.
13. The method of claim 1, wherein for a duration of at least 2 weeks following administration of the first dose of temozolomide, the patient receives two doses each week of a therapeutically effective amount of a formulation comprising ABDNAZ.
14.-35. (canceled)
36. The method of claim 1, wherein the formulation comprising ABDNAZ contains dimethylacetamide, water, and a polyethylene glycol.
37. The method of claim 36, wherein the polyethylene glycol has a number-average molecular weight of about 400 g/mol.
38. The method of claim 1, wherein the glioma is subjected to radiation therapy once per day for at least 3 days within a 7 day period following administration of the first dose of temozolomide.
39. The method of claim 1, wherein the glioma is subjected to radiation therapy once per day for at least 5 days within a 7 day period following administration of the first dose of temozolomide.
40.-47. (canceled)
48. The method of claim 1, wherein when radiation therapy is administered to the glioma, the amount of radiation provided to the glioma on the day of administering the radiation therapy is from about 1 Gy to about 3 Gy.
49.-52. (canceled)
53. The method of claim 1, wherein after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 2 weeks.
54.-56. (canceled)
57. The method of claim 1, wherein after receiving temozolomide for a duration of 6 weeks, the patient does not receive any of temozolomide, radiation therapy, or ABDNAZ for a duration of at least about 4 weeks.
58.-68. (canceled)
69. A method of treating a glioma in a patient, comprising the steps of:
(a) administering to the patient in need thereof a therapeutically effective amount of a formulation comprising irinotecan, and within about 7 days subjecting the glioma to radiation therapy; and
(b) administering to the patient at least one dose of a therapeutically effective amount of a formulation comprising ABDNAZ within about 7 days of administration of a first dose of the irinotecan; to treat the glioma;
wherein each dose of the formulation comprising ABDNAZ is administered to the patient by intravenous infusion providing ABDNAZ in an amount of from about 0.1 mg to about 20 mg.
70.-107. (canceled)
108. The method of claim 69, wherein the glioma is an astrocytoma.
109. The method of claim 69, wherein the glioma is a malignant astrocytoma.
110. The method of claim 69, wherein the glioma is a glioblastoma.
111.-112. (canceled)
113. The method of claim 69, wherein the patient is an adult human.
114.-115. (canceled)
116. The method of claim 69, wherein there is at least a 35% reduction in the size of at least one glioma tumor in the patient.
117.-118. (canceled)
119. The method of claim 69, wherein there is at least a 35% reduction in the number of glioma tumors in the patient.
120. (canceled)
US16/712,148 2015-10-29 2019-12-12 Treatment of gliomas using organonitro compound combination therapy Abandoned US20200375982A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/712,148 US20200375982A1 (en) 2015-10-29 2019-12-12 Treatment of gliomas using organonitro compound combination therapy
US17/223,422 US11701351B2 (en) 2015-10-29 2021-04-06 Treatment of gliomas using organonitro compound combination therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562247846P 2015-10-29 2015-10-29
US15/337,378 US9987270B1 (en) 2015-10-29 2016-10-28 Treatment of gliomas using organonitro compound combination therapy
US15/989,862 US10543208B2 (en) 2015-10-29 2018-05-25 Treatment of gliomas using organonitro compound combination therapy
US16/712,148 US20200375982A1 (en) 2015-10-29 2019-12-12 Treatment of gliomas using organonitro compound combination therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/989,862 Continuation US10543208B2 (en) 2015-10-29 2018-05-25 Treatment of gliomas using organonitro compound combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/223,422 Continuation US11701351B2 (en) 2015-10-29 2021-04-06 Treatment of gliomas using organonitro compound combination therapy

Publications (1)

Publication Number Publication Date
US20200375982A1 true US20200375982A1 (en) 2020-12-03

Family

ID=62235166

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/337,378 Active US9987270B1 (en) 2015-10-29 2016-10-28 Treatment of gliomas using organonitro compound combination therapy
US15/989,862 Active US10543208B2 (en) 2015-10-29 2018-05-25 Treatment of gliomas using organonitro compound combination therapy
US16/712,148 Abandoned US20200375982A1 (en) 2015-10-29 2019-12-12 Treatment of gliomas using organonitro compound combination therapy
US17/223,422 Active US11701351B2 (en) 2015-10-29 2021-04-06 Treatment of gliomas using organonitro compound combination therapy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US15/337,378 Active US9987270B1 (en) 2015-10-29 2016-10-28 Treatment of gliomas using organonitro compound combination therapy
US15/989,862 Active US10543208B2 (en) 2015-10-29 2018-05-25 Treatment of gliomas using organonitro compound combination therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/223,422 Active US11701351B2 (en) 2015-10-29 2021-04-06 Treatment of gliomas using organonitro compound combination therapy

Country Status (1)

Country Link
US (4) US9987270B1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008287B2 (en) 2016-10-14 2021-05-18 Epicentrx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine
US11160784B1 (en) 2015-10-20 2021-11-02 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
US11576895B2 (en) 2016-01-11 2023-02-14 Epicentrx, Inc Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
US11660286B2 (en) 2011-10-07 2023-05-30 Epicentrx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US11701351B2 (en) 2015-10-29 2023-07-18 Epicentrx, Inc. Treatment of gliomas using organonitro compound combination therapy
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
US11925617B2 (en) 2005-08-12 2024-03-12 Northrop Grumman Systems Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116917009A (en) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 Rack for particle therapy system
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2978453A (en) 1956-12-12 1961-04-04 Aerojet General Co 3, 3, 5, 5-tetranitropiperidine
JPS4830376B1 (en) 1970-12-29 1973-09-19
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5511509A (en) 1978-07-07 1980-01-26 Toomasu Gorudon Robaato Cancer therapy
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8728418D0 (en) 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (en) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli
US5693794A (en) 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (en) 1990-11-13 1997-09-30 株式会社日立製作所 Display control device
TW198712B (en) 1991-04-17 1993-01-21 Hoffmann La Roche
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE69226197T2 (en) 1991-11-08 1999-02-11 Somatogen, Inc., Boulder HEMOGLOBINE AS A MEDICINE DELIVERY SYSTEM
DE4226974C2 (en) 1992-08-14 1994-08-11 Fresenius Ag Method and device for the continuous preparation of a cell suspension
US5336784A (en) 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
ATE374607T1 (en) 1994-05-27 2007-10-15 Strakan Int Ltd COMPOSITION CONTAINING NITROGEN OXIDE DONATORS AND METHOD FOR TREATING ANAL DISEASES
ZA962077B (en) 1995-03-14 1997-03-26 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
IL117474A (en) 1995-03-14 2001-04-30 Siemens Ag Removable precision dosating unit containing inhalation medicaments for ultrasonic atomizer device
WO1996036602A1 (en) 1995-05-15 1996-11-21 The United States Of America Adnaz, compositions and processes
US5580988A (en) 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
BR9712530A (en) 1996-10-11 1999-10-19 Warner Lambert Co Interleukin-1beta converting enzyme asparate ester inhibitors
EP0932591A1 (en) 1996-10-15 1999-08-04 Eastman Chemical Company Explosive formulations
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
US7635722B1 (en) 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6391911B1 (en) 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
US20020077276A1 (en) 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
EA005409B1 (en) 2000-04-10 2005-02-24 Пфайзер Продактс Инк. Benzoamide piperidine containing derivatives as substance p receptor antagonists
JP2002069057A (en) 2000-07-07 2002-03-08 Kyowa Hakko Kogyo Co Ltd Piperidine derivative
DE10111049A1 (en) 2001-03-06 2002-09-12 Beiersdorf Ag Cosmetic or dermatological preparations for combating inflammatory disorders or dryness of the skin, containing agents inhibiting the onset of nitrogen monoxide synthase activity
EP1459724B1 (en) 2001-12-28 2013-11-20 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003282534A1 (en) 2002-10-07 2004-05-04 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
EP1603933A2 (en) 2003-03-13 2005-12-14 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
ATE500216T1 (en) 2003-06-25 2011-03-15 Je Il Pharmaceutical Co Ltd TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
EP1653978B1 (en) 2003-07-09 2020-06-03 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of nitrite salts for the treatment of cardiovascular conditions
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
RU2265440C2 (en) 2004-01-13 2005-12-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Method for pre-operational treatment of mammary cancer
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc DERIVATIVES OF QUINAZOLIN AS METABOLICALLY INERT ANTIFOLIC
WO2006102760A1 (en) 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
EP1996550A2 (en) 2005-09-27 2008-12-03 Novartis AG Carboxyamine compounds and their use in the treatment of hdac dependent diseases
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
CN200946766Y (en) 2006-06-09 2007-09-12 刘余厚 Bushing type ultraviolet lamp
US8122281B2 (en) 2007-04-13 2012-02-21 International Business Machines Corporation System and method for dependent failure-aware allocation of distributed data-processing systems
RU2411953C1 (en) 2009-09-02 2011-02-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт" Федерального агентства по высокотехнологичной мед. помощи Method of treating mammary gland cancer
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
WO2012078992A1 (en) 2010-12-09 2012-06-14 Radiorx, Inc. Organonitro compounds for use in treating non-hodgkin's lymphoma and leukemia, and methods relating thereto
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
CA2850723C (en) 2011-10-07 2019-07-09 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
US20140220163A1 (en) 2014-02-04 2014-08-07 Hamzeh Soleimani Babadi Powder mixture composition of natural materials for controlling deficiencies in polypeptide alpha and beta hemoglobin chains
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
SG11201805942UA (en) 2016-01-11 2018-08-30 Epicentrx Inc Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
EA201990949A1 (en) 2016-10-14 2019-10-31 SULPHOXIALKYL ORGANIC NITRO COMPOUNDS AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE
IL311727A (en) 2017-07-07 2024-05-01 Epicentrx Inc Compositions for parenteral administration of therapeutic agents
WO2019164594A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. METHODS AND COMPOSITIONS UTILIZING RRx-001 FOR RADIOPROTECTION
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
US12048793B2 (en) 2018-06-11 2024-07-30 Epicentrx, Inc. Medication infusion devices, systems, and methods
BR112022010596A2 (en) 2019-12-11 2022-08-16 Epicentrx Inc DRUG INFUSION DEVICES, SYSTEMS, AND METHODS

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11925617B2 (en) 2005-08-12 2024-03-12 Northrop Grumman Systems Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US11660286B2 (en) 2011-10-07 2023-05-30 Epicentrx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US11160784B1 (en) 2015-10-20 2021-11-02 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US11701351B2 (en) 2015-10-29 2023-07-18 Epicentrx, Inc. Treatment of gliomas using organonitro compound combination therapy
US11576895B2 (en) 2016-01-11 2023-02-14 Epicentrx, Inc Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
US12357607B2 (en) 2016-01-11 2025-07-15 Epicentrx, Inc. Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
US11008287B2 (en) 2016-10-14 2021-05-18 Epicentrx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
US12357608B2 (en) 2018-01-08 2025-07-15 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection

Also Published As

Publication number Publication date
US11701351B2 (en) 2023-07-18
US9987270B1 (en) 2018-06-05
US20190125742A1 (en) 2019-05-02
US10543208B2 (en) 2020-01-28
US20220054480A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US11701351B2 (en) Treatment of gliomas using organonitro compound combination therapy
US6333348B1 (en) Use of docetaxel for treating cancers
Becker et al. Status quo—standard-of-care medical and radiation therapy for glioblastoma
Rao et al. Axitinib sensitization of high single dose radiotherapy
Lanzolla et al. Sirolimus as a second-line treatment for Graves’ orbitopathy
US20250177364A1 (en) Combination therapies for breast cancer
Kordbacheh et al. Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab
JP2016074746A (en) Antineoplastic combinations containing hki-272 and vinorelbine
Bogan et al. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: efficacy, toxicity and stability in rabbits models and patients
Wu et al. 381O First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
LoRusso et al. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Lai et al. Sirolimus versus mycophenolate mofetil for triple immunosuppression in thyroid eye disease patients with recent‐onset intractable diplopia: A prospective comparative case series.
MX2013008798A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme.
US20170348284A1 (en) Use of marizomib for the treatment of central nervous system (cns) cancers
Naegel et al. Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke‐like episodes syndrome: A case report
JPWO2012105610A1 (en) Pharmaceutical for prevention or treatment of diseases associated with intraocular neovascularization and / or increased intraocular vascular permeability
KR20230050363A (en) Use of BTK inhibitors in the treatment of diseases
WO2021175824A1 (en) Method for administration of an anti cancer agent
US11285143B2 (en) Use of mTOR inhibitor and chloroquine for treating cancer
US20070254871A1 (en) Compounds for the Treatment of Inflammation of the Central Nervous System
JP2023138528A (en) Enhancement of tumor chemotherapeutic response via activation of the ASMASE/ceramide pathway by timed administration of short-acting anti-angiogenic agents
Dunbar et al. CTNI-59. A MULTICENTER OBSERVATIONAL STUDY OF CS-131 SEEDS EMBEDDED IN A COLLAGEN CARRIER TILE FOR NEWLY DIAGNOSED AND RECURRENT OPERABLE INTRACRANIAL NEOPLASMS–TRIAL IN PROGRESS
Ikeda et al. Mizoribine synchronized methotrexate therapy should be considered when treating rheumatoid arthritis patients with an inadequate response to various combination therapies
Heetla et al. Intrathecal administration of clozapine to reduce side effects: A hypothesis
Katz Testing Drug Induced Improvements in Outer Retina Mitochondria Activity Based on Optical Coherence Tomography Biomarkers

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION